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Abstract 
A class of glial cell, astrocytes are highly abundant in the CNS. In addition to maintaining 
tissue homeostasis, astrocytes regulate neuronal communication and synaptic plasticity. 
There is an ever-increasing appreciation that astrocytes are involved in the regulation of 
physiology and behaviour in normal and pathological states, including within 
neuroendocrine systems. Indeed, astrocytes are direct targets of hormone action in the 
CNS, via receptors expressed on their surface, and are also a source of regulatory 
neuropeptides, neurotransmitters, and gliotransmitters. Furthermore, as part of the 
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neurovascular unit, astrocytes can regulate hormone entry into the CNS. This review is 
intended to provide an overview of how astrocytes are impacted by and contribute to the 
regulation of a diverse range of neuroendocrine systems: energy homeostasis and 
metabolism, reproduction, fluid homeostasis, the stress response, and circadian rhythms. 
 
Astrocytes are a type of glial cell abundant in the central nervous system (CNS). Although 
historically known for their role in maintaining tissue homeostasis, there is a growing 
recognition that astrocytes actively contribute to the regulation of physiology and behaviour 
via modulation of neuronal circuits. The goal of this review is to provide an overview of the 
emerging contribution of astrocytes in neuroendocrine function, highlighting other recent 
in-depth reviews and key studies for those wishing to explore specific areas further. Related 
to astrocytes, tanycytes are a specialised glial-cell type lining the base of the third ventricle 
in the hypothalamus. While our understanding of the importance of tanycytes in 
neuroendocrine function is evolving, in the interest of focus they will not feature in this 
article and we refer the readers to other recent reviews in this area (1, 2). Although the 
pituitary gland contains glial cells with morphological similarities to astrocytes, namely 
pituicytes (3), these will not feature in this review.  
 
An overview of astrocyte function 
Astrocytes are found throughout the CNS, but the ratio of astrocytes to neurons varies 
depending on the brain region. For a comprehensive overview of the cellular physiology of 
astrocytes we refer the readers to the recent review by Verkhratsky and Nedergaard (4). 
Astrocytes utilise variations in intracellular Ca2+ as their main ionic signalling modality and, 
in contrast to neurons, are not directly electrically excitable.  
 
Astrocytes regulate tissue homeostasis within the brain including supplying energy 
substrates to neurons, maintaining pH and ionic balance. Importantly, they also functionally 
modulate neuronal activity in several ways (4): 1) regulation of ion and neurotransmitter 
availability (via modulating synthesis, uptake, and recycling); 2) releasing gliotransmitters 
such as ATP/adenosine, lactate and D-serine; 3) modulating blood brain barrier (BBB) 
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permeability and thus controlling entrance and efflux of substances to/from the brain; 4) 
providing a plastic physical barrier to extra-synaptic neuronal communication through 
ensheathment of synapses, and 5) regulating synaptic stability. Additionally, astrocytes can 
regulate neuronal growth (5) and the formation and elimination of synapses during brain 
development (6-9).  
 
Astrocytes are heterogeneous 
Astrocytes are heterogeneous in both their morphology and function (10, 11). These 
differences can be seen both between and within different regions of the brain. Astrocyte 
heterogeneity arises partly during development (12); however, plasticity allows astrocytes 
to change in both form and function in response to physiological and pathological changes 
within the brain, including in response to aging (13). For example, during brain damage and 
neurological disease, astrocytes undergo morphological and functional changes termed 
reactive astrogliosis (14). This process has many roles in neuropathology: forming “glial-
scars” which separate healthy and diseased tissue (15), enabling phagocytic activity in 
astrocytes (16), and stimulating astrocytes to become mediators which regulate immune 
cell recruitment in the CNS (15).  
 
Transcriptional analyses indicate that neurodegenerative diseases and aging are 
characterised by the formation of “A1-like” reactive neuroinflammatory astrocytes, which 
have lost neurotrophic capacity and instead contribute to death of neurons and 
oligodendrocytes via release of toxic factors (17, 18). In contrast, ischemic injury is 
characterised by a predominance of an “A2-like” phenotype amongst the reactive 
astrocytes, in which astrocyte expression of genes which promote neuronal growth, 
survival, and synapse repair are increased (19). Understanding astrocyte heterogeneity and 
the creation of functional classifications is an evolving area and, as is the case with 
peripheral immune cells (20), phenotypes are likely to be on a plastic continuum depending 
on variations in microenvironmental conditions within the CNS. 
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Glial-fibrillary acidic protein (GFAP) is an intermediate filament protein and commonly used 
cellular marker astrocytes throughout the brain, although it is also expressed in tanycytes 
and ependymal cells (21). The GFAP is promotor used experimentally to drive targeted 
genetic-modification of astrocytes in vitro and in vivo. While GFAP levels are increased in 
reactive astrocytes and it is used histologically to visualise morphological changes in 
astrogliosis, it is important to note not all astrocytes, including those in the hypothalamus, 
express detectable levels of GFAP. Indeed, when GFAP-immunoreactivity is used to quantify 
changes astrocyte number in response to different experimental or physiological 
manipulations, it is not necessarily clear whether additional numbers of GFAP-
immunoreactive cells reflect astrocyte proliferation or the rise of detectable levels of GFAP 
pre-existing astrocytes. Other frequently used markers of astrocytes include GLAST, GLT-1 
and S100B, although the relative specificity of these is age and brain region specific. 
Aldehyde dehydrogenase 1 family member L1 (Aldh1L1) is emerging as a specific pan-
astrocyte marker (22) and the Aldh1L1 promotor is increasingly being used to facilitate 
genetic modification of astrocytes. Moving forward, use of both GFAP and Aldh1L1 
expression (gene and protein) will give a more holistic picture of astrocyte form and 
function than assessment of GFAP levels alone. 
 
The remainder of this review will be focused on evidence for astrocytic involvement in 
neuroendocrine regulation, largely focusing on hypothalamic astrocytes, but touching on 
astrocytes in other brain regions where pertinent information is available. 
 
Astrocytes are key players in neuroendocrine regulation 
Astrocytes are direct targets of hormone action via receptors expressed on their surface. As 
such, hormones can impact astrocyte morphology and function including regulating 
neurotransmitter availability, and release of gliotransmitters and active metabolic 
intermediates, which can in turn influence neuronal communication. Astrocytes are also a 
source of bioactive signalling molecules in the brain: neuropeptides, neurosteroids, and 
hormones (via direct synthesis or processing of precursors, by enzymes such as deiodinase 
2, following their uptake into astrocytes by specific transporters). As part of the 
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neurovascular unit, astrocytes can also directly influence BBB permeability and thereby may 
regulate entrance and efflux of hormones, and other key neuroendocrine modulators such 
as nutrients and cytokines, from the brain (23). A summary of the proposed mechanisms by 
which astrocytes regulate the activity of neuroendocrine systems is illustrated in Figure 1. 
Astrocytes impact the activity of a variety of neuroendocrine systems, introduced 
individually below. 
 
Astrocytes and the neuroendocrine regulation of energy homeostasis and metabolism 
Food intake and body weight 
The study of astrocytes in the central control of energy homeostasis has been a growing 
field in recent years. The discovery that consumption of a high-fat diet increases mRNA for 
known inflammatory molecules in the rat hypothalamus drew attention to hypothalamic 
inflammation as an area of study (24). Within the hypothalamus nuclear factor kappa B (NF-
κB) is activated in diet-induced obesity (DIO) and virally-mediated genetic activation of IKKβ, 
a kinase known to activate NF-κB, in the mouse hypothalamus is sufficient to induce insulin 
and leptin resistance (25). Moreover, DIO increases glial-fibrillary acidic protein (GFAP; a 
commonly used marker of astrocytes) gene expression and astrocytic ensheathment of 
proopiomelanocortin neurons (POMC) in the arcuate nucleus (ARC), consequently 
decreasing the number of synaptic inputs to POMC neurons; thus, reducing neural activity 
critical for the inhibition of food intake (26). Following this seminal study, other groups have 
demonstrated that DIO in rodents is accompanied by an increase in GFAP expression (both 
at the gene and protein level) and altered morphology of astrocytes in the ARC and other 
hypothalamic nuclei (27, 28). This astrogliosis is also seen in melanocortin-4 receptor 
deficient mice, which become obese on standard chow diet, due to excess intake (27), 
suggesting that the gliosis can occur because of obesity in the absence of high-fat diet 
consumption. Returning DIO mice to a standard chow diet results in weight loss and reversal 
of the astrogliosis (29), highlighting the plastic nature of this response. The physiological 
significance of these changes is reinforced by studies indicating that inducing inflammatory 
signalling in astrocytes results in obesity, while preventing inflammation preserves 
astrocytic plasticity protecting against DIO (30). Supporting this supposition, brain-wide 
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deletion of astrocyte IKKβ during the induction of DIO is protective against hypothalamic 
inflammation and prevents subsequent weight gain (31). While supportive evidence for 
obesity-associated glial changes from human studies is limited, there is a positive 
correlation between body mass index and signatures of hypothalamic gliosis, measured by 
hyper-intensity in magnetic resonance imaging scans (28). Together, these studies implicate 
astrocyte inflammatory processes, plausibly initiated by IKKβ, in the development and 
maintenance of DIO possibly via a loss of astrocyte structural plasticity.  
 
The response of hypothalamic astrocytes in rodents to a high-fat diet appears to be 
biphasic: there is an initial increase in expression GFAP and pro-inflammatory markers 
during the first 24-72h on a high-fat diet, which then transiently subsides before returning 
after 14 days on the diet (28, 32, 33). The first phase of astrocyte activation may occur 
independently of leptin resistance (32). Inhibition of astrocyte NF-κB mediated 
inflammatory signalling during the initial phase of high-fat diet-induced astrogliosis 
abolishes changes in GFAP expression and augments high-fat diet-induced binge eating in 
mice (33). This has led to the suggestion that the initial phase of astrogliosis is partly a 
homeostatic or allostatic physiological response to maintain energy balance while the 
second inflammatory phase is a pathophysiological manifestation of prolonged deviation 
from energy homeostasis. Further evidence for a role of astrocytes in the physiological 
response to energy imbalance comes from experiments where mice are pushed out of 
homeostasis into negative energy balance by fasting. In common with acute energy excess 
associated with feeding a high-fat diet, fasting impacts hypothalamic astrocyte signalling 
(30, 34, 35). Together these studies indicate that hypothalamic astrocytes are sensitive to 
acute deviations in energy homeostasis. 
 
Astrocytes can directly sense and respond to appetite-modulating hormones via receptors 
expressed on their surface. Astrocytes neighbouring the third ventricle (3V) that are 
sensitive to peripheral cues express leptin receptors (36). Diet-induced and genetic obesity 
increases the number of leptin receptor-expressing astrocytes in the ARC and dorsomedial 
nucleus (DMN) of the hypothalamus (37, 38). Functional studies indicate that chronic (14 
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day) intracerebroventricular (ICV) delivery of exogenous leptin increases hypothalamic 
expression of GFAP and vimentin and increases astrocyte process length. The same 
treatment reduces expression of synaptic proteins, suggesting increased glial ensheathment 
of neurons obstructing synapse formation, which may impair integration of feeding cues by 
these neurons (39). ICV delivery of leptin for 14 days also decreases the expression of 
astrocyte glucose and glutamate transporters in the hypothalamus, possibly leading to 
elevated synaptic glutamate (35). A study utilising a mouse model where leptin receptors 
were selectively deleted from astrocytes in adult mice revealed reduced ensheathment of 
ARC neurons by astrocytes lacking the leptin receptor (40). In accordance with this, these 
mice showed reduced sensitivity to leptin and increased sensitivity to ghrelin. These results 
suggest leptin receptors on astrocytes are crucial for anatomical wiring of the ARC 
melanocortin circuits critical for the regulation of energy homeostasis and that this wiring 
ensures appropriate responses to endocrine signals that modulate food intake. A second 
mouse model with developmental astrocyte-specific deletion of leptin receptors showed an 
increased body-weight and fat-mass gain on a high fat diet, accompanied by greater 
hypothalamic leptin resistance and increased gliosis compared with wild-type controls (41). 
Astrocyte sensing of leptin also appears to be critical during hypothalamic development 
(42).  
 
Like leptin, ICV treatment with the orexigenic hormone ghrelin regulates the expression of a 
number of proteins expressed by hypothalamic astrocytes including structural proteins 
(GFAP and vimentin) and transporters (glucose and glutamate transporters) (43). In vitro 
primary mouse astrocytes, primary rat astrocytes and the C6 astrocytoma cell line are 
responsive to ghrelin, while glia cultured from mice lacking the growth-hormone 
secretagogue receptor 1A (GHSR-1A) do not, suggesting some of the effects of ghrelin may 
be due to direct activation of astrocyte GHSR-1A (43-45). This is supported by 
immunohistochemistry which has identified GHSR-1A co-localised with GFAP in the rat 
hypothalamus (43). Together these studies provide evidence that astrocytes are direct 
sensors of endocrine signals regulating energy balance, and likely mediate, at least in part, 
some of the physiological effects of these hormones in the CNS. 
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The application of opto- and chemo-genetic technologies for manipulation of ARC astrocyte 
signalling has provided conflicting results with respect to astrocytic regulation of feeding 
behaviour. In 2015, Yang and colleagues reported that chemogenetic activation of Ca2+ 
signalling in ARC astrocytes caused a decrease in both nocturnal feeding and ghrelin-
induced food intake while enhancing the satiating effect of leptin. Their work suggests this 
was mediated by astrocyte-derived adenosine inhibiting agouti-related peptide (AgRP) 
neurons via activation of pre-synaptic adenosine A1 receptors (46). This was supported by 
follow-up study from the same group, which showed that optogenetic-mediated activation 
ARC astrocyte signalling reduced food intake (47). However, in contrast a second 
independent research group, employing a similar chemogenetic methodology, found that 
activating Ca2+ signalling hypothalamic astrocytes increased food intake during the dark 
phase by excitation of AgRP neurons (34). The discrepancies in these results may be due to 
technical differences (e.g. injection of virus, dose of chemogenetic ligand) or may represent 
a state-dependent effect of astrocyte activation on feeding behaviour. As such, much 
remains to be learnt about the contribution of astrocytes to hypothalamic control of 
feeding. 
 
Although not as widely studied in this context, astrocytes outside the hypothalamus may 
also play a role in regulating food intake given that they can control some consummatory 
behaviours. For example, activation of nucleus accumbens (NAc) core astrocytes reduces 
the self-administration of cocaine after reinstatement via an increase in synaptic glutamate 
(48). The process of cocaine self-administration and extinction appears to render NAc core 
astrocytes hypoactive, suggesting they play a role in addiction (49). Given that NAc neurons 
are thought to be involved in driving the motivation to feed (50), astrocyte regulation of 
transmission in this circuit may alter feeding, although this remains to be investigated. A 
second population of extra-hypothalamic astrocytes shown to influence food intake are 
those in the nucleus of the solitary tract (NTS). NTS astrocytes appear to play a role in 
glucagon-like peptide (GLP-1) mediated-satiety since these cells show increases in 
intracellular Ca2+ in response to the GLP-1 receptor agonist exendin-4 in an ex vivo rat brain 
slice. In rats, delivery of exendin-4 to the NTS reduces food intake, an effect that is abolished 
by pre-treatment with the astrocyte metabolic inhibitor fluorocitrate (51). The exact 
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mechanism for this effect remains unclear as GLP-1 receptors were not observed on 
astrocytes in mice expressing green fluorescent protein in GLP-1 receptor containing cells 
(52). 
 
To conclude, astrocytes in the hypothalamus are responsive to short-term and prolonged 
deviations in energy homeostasis. These cells can directly sense appetite-regulating 
hormones and adjust morphology, expression of transporters, and potentially release of 
gliotransmitters accordingly, to alter the firing of neurons that control food intake. Extra-
hypothalamic astrocytes may play a role in food intake which will be an emerging area for 
future research. A schematic summary of the current understanding of how astrocytes may 
impact feeding behaviour can be found in Figure 2. 
 
Glucose homeostasis 
Glycaemia regulation is largely controlled by the pancreas, principally by glucose-dependent 
insulin secretion from pancreatic β-cells through Ca2+ dependent exocytosis1. In health, 
insulin secretion is largely sufficient to control blood glucose within the healthy range (4-
7mM glucose). When β-cells are compromised, such as in type 1 diabetes, or when insulin 
action is insufficient to adequately control glucose levels, such as during early type 2 
diabetes, other tissues, such as the brain, play a more prominent role. 
 
In the CNS, blood glucose is mainly regulated by the hypothalamus, with the hindbrain also 
playing an important role. POMC, AgRP, and neuropeptide Y (NPY) neurons of the ARC and 
steroidogenic factor-1 (SF-1) neurons of the ventromedial nucleus of the hypothalamus 
(VMN) all modulate glucose homeostasis through regulation of food intake and pancreatic 
hormone release (53-55).  
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Given that astrocytes are near the cerebral blood supply and directly interact with pericytes 
which regulate vascular tone, it is likely that astrocytes detect changes in glucose levels 
before neurons. Over the past decade several studies have demonstrated that astrocytes 
detect changes in glucose availability, and direct manipulation of astrocyte function alters 
glycaemia and/or glucose tolerance. For example, glucose insufficiency induced by 2-
deoxyglucose (2-DG) increases intracellular Ca2+ in hindbrain astrocytes (56). This astrocyte 
activation is required for the stimulation of adjacent catecholamine neurons, indicating that 
astrocytes couple glucose availability to neuronal activation (56). Catecholamine neurons 
stimulate the release of adrenaline, contributing to the counterregulatory response (CRR) to 
hypoglycaemia, suggesting astrocytes play a role in the CRR. Rats exposed to three days of 
recurrent insulin-induced hypoglycaemia have reduced hypothalamic expression of the main 
astrocytic glutamate transporter GLT-1. This correlates with reduced glutamate uptake in 
primary cultured rat astrocytes, and to glutamatergic neurotransmission failure in vivo, 
attenuating activation of the CRR (57). Further supporting an astrocytic role in full activation 
of the CRR to hypoglycaemia, loss of the brain glucose transporter GLUT2 causes loss of the 
glucagon response to hypoglycaemia in mice. Rescue of GLUT2 levels specifically in GFAP-
expressing astrocytes is sufficient to restore the glucagon response to hypoglycaemia, 
suggesting that astrocytic glucose sensing is essential to maintaining glucose homeostasis 
(58). In addition, stimulation of the CRR following fourth ventricular (4V) administration of 
2-DG is ablated following pre-treatment with glial metabolic inhibitor fluorocitrate, 
indicating that astrocytes neighbouring the 4V are also required for activation of the CRR. 
These data suggest changes in hypothalamic and hindbrain astrocyte function are required 
for full activation of the CRR to hypoglycaemia.  
 
In addition to astrocytic GLUT2 restoring the CRR as discussed above, there is further 
evidence that astrocyte function is directly regulated by glucose availability. Insulin receptor 
deletion from hypothalamic astrocytes in mice reduces astrocytic intracellular glucose levels 
and astrocytic ramification (59), reducing the physical contact between neurons and 
astrocytes. Sensitivity to changes in glucose availability and subsequent communication of 
POMC neurons is also reduced. This induces glucose intolerance, likely mediated by reduced 
brain glucose transporter GLUT1 expression (59). Interestingly, in a separate study, 
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overexpression of GLUT1 in GFAP-containing cells was sufficient to rescue diabetic 
hyperglycaemia induced by STZ (streptozotocin) administration (60). Taken together, these 
data suggest that increased or decreased glucose delivery into hypothalamic astrocytes (via 
GLUT1) is key in the central sensing of glucose and subsequent regulation of peripheral 
glucose levels.  
 
In the CNS glycogen is stored predominantly in astrocytes (61). In astrocytes, as in the 
periphery, glycogen synthesis is dependent upon insulin receptor activation through the 
PI3K/Akt pathway to increase intracellular glycogen storage during glucose sufficiency. 
Although the glycogen content of astrocytes is low compared to liver and skeletal muscle, it 
is biologically meaningful. Glycogen breakdown by glycogenolysis is required to sustain 
neural activity during glucose deprivation (62). Moreover, astrocytic glycogen 
supercompensation is postulated to contribute to CRR failure following recurrent 
hypoglycaemia. For example, in mice hypothalamic glycogen content doubles in response to 
repeated once daily brain injection of 2-DG to simulate recurrent hypoglycaemia (63). On 
recovery from insulin-induced hypoglycaemia in mice, brain glycogen content has been 
reported to increase by 25% over basal levels, suggesting short term glycogen 
supercompensation. This may be a species-specific phenomenon as little or no glycogen 
supercompensation has been described in rat hypothalamus after hypoglycaemia (64). 
However, some glycogen supercompensation has been observed in cortex, striatum and 
hippocampus following acute hypoglycaemia in rats (65). Whether glycogen 
supercompensation following acute/recurrent hypoglycaemia occurs in humans with 
diabetes remains uncertain (66). 
In both STZ-induced diabetes and the non-obese diabetic (NOD) mouse models increased 
hippocampal astrogliosis has been observed reflected in both increased number of GFAP-
immunoreactive cells and increased cellular area (67). Conversely, in rats with poorly-
controlled diabetes (STZ-induced) the number of hypothalamic GFAP-immunoreactive cells 
decreased within 6 weeks of poor glucose control, likely mediated by increased astrocytic 
cell death (68, 69). As discussed above, in humans and in rodent models, obesity which is 
often concurrent with elevated glucose levels, also causes hypothalamic gliosis and 
inflammation (28). 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Glucose intolerance driven by high-fat diet challenge also has an astrocytic component. For 
example, astrocyte-specific inducible knockout of the NF-κB activating molecule IKKβ 
improves glucose intolerance caused by DIO, restoring glucose handling and insulin 
sensitivity in addition to reducing astrogliosis in the medial basal hypothalamus/ARC (30). 
Additionally, astrocyte-specific constitutive activation of IKKβ causes glucose intolerance in 
chow fed mice through a mechanism involving increased extracellular GABA preventing the 
release of the growth hormone brain derived neurotrophic factor (BDNF) (30). Together 
these data suggest that inflammatory astrogliosis mediated by the NF-κB transcription 
factor dysregulates glucose homeostasis through increased GABA and reduced BDNF 
release. 
 
In summary, astrocytes play a crucial role in maintaining glucose homeostasis by regulating 
the hypoglycaemic CRR through direct glucose sensing and conversely synthesising and 
storing glycogen when sufficient glucose is available. Beyond this, astrocytes activate 
neuronal networks implicated in endocrine glucose regulation through NF-κB activation, and 
glutamate and GABA signalling in direct response to availability of glucose, insulin and 
glucagon. A schematic of the current understanding of how astrocytes may impact systemic 
glucose homeostasis can be found in Figure 3. 
 
Thyroid hormone axis 
The hypothalamic-pituitary-thyroid (HPT) axis is a key neuroendocrine feedback system 
regulating growth, development, and metabolism, which when impaired also impacts 
reproductive capacity and cognition.  Thyrotropin releasing hormone (TRH) neurons in the 
hypothalamus project to the anterior pituitary thyrotropes and stimulate the release of 
thyrotropin/thyroid stimulating hormone (TSH) which in turn stimulates thyroxine (T4), and 
to a lesser degree 3,3’,5-triiodothyronine (T3), from the thyroid gland.  Plasma T4 and T3, 
and T3 locally produced in the brain, provide negative feedback regulating the production of 
TRH and TSH. Limited evidence, largely from in vitro studies, suggests that astrocytes may 
be direct targets of action of TRH via receptors expressed on their surface (70-72) but the 
physiological relevance of this remains unclear. 
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Astrocytes express a variety of thyroid hormone transporters (73). Whether these cells 
actively participate in transport of thyroid hormones into the brain across the BBB is 
uncertain (74), but once in the CNS, thyroid hormones are taken up into astrocytes and 
tanycytes which mediate local conversion of T4 to T3 by type-2 deiodinase 2 (D2) (75, 76). 
The half-life of D2 is regulated by the presence of T4: when T4 levels are low the half-life of 
D2 is increased and vice versa (77). However, within the hypothalamus T4-induced D2 
regulation is minimal and D2 activity is preserved even when T4 levels are high, enabling the 
hypothalamus to maintain higher sensitivity to T4 (78). Within the hypothalamus, endocrine 
action of plasma T3 and paracrine action of locally produced T3 on TRH neurons are part of 
the negative feedback loop which inhibits HPT axis activity. In mice, genetically mediated 
germ-line deletion of the deiodinase 2 gene (DIO2) specifically from GFAP-expressing cells 
(encompassing a population of astrocytes) reduces D2 activity in the cortex, hippocampus 
and cerebellum, but not the hypothalamus indicating that tanycytic D2 and not astrocytic 
D2 is likely responsible for mediating T4 to T3 conversion within this brain region (79). This 
was further supported by the fact that loss of D2 in GFAP-expressing cells did not result in 
HPT-axis dysfunction or alterations in the morphology of the thyroid. However, despite no 
overt changes in growth curves, body composition or feeding behaviour, these animals 
show subtle changes in whole body metabolism consistent with changes in substrate 
utilization suggesting a contribution of D2-generated T3 in the brain, mostly likely the 
hypothalamus and/or brainstem, in influencing systemic energy homeostasis (80). 
Astrocyte function is directly modulated by thyroid hormones, which in turn can modulate 
neuronal activity. Exposure of primary human astrocytes in culture to T3 stimulates fatty-
acid oxidation and ATP production (81). Neurotrophin-3 and basic fibroblast growth factor 
(FGF-2) have been implicated as factors released from astrocytes in response to T3 which 
impact neuronal activity (82). In addition to modulating gliotransmitter release, in vitro 
studies demonstrate that T3 enhances glutamate uptake into astrocytes by increasing the 
activity of astrocyte glutamate transporters GLT-1 and GLAST (83), which could in turn 
impact communication between neurons by altering the glutamate availability in the 
synaptic cleft. Together these data suggest that in addition to contributing to controlling 
thyroid hormone signalling in the brain by regulating local T3 levels, autocrine or paracrine 
activity of T3 on astrocytes in the CNS may modulate neuronal communication.  
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It remains to be determined whether astrocytes form part of the negative feedback loop 
that regulates HPT-axis function by modulating activity of TRH neurons. Furthermore, it is 
unclear how the effects of T3 on astrocyte activity are mediated, as the presence of thyroid 
hormone receptors in astrocytes is controversial (84) so more work is needed in this area. 
 
Astrocytes and the neuroendocrine regulation of reproductive function 
Hypothalamic-pituitary-gonadal (HPG) axis 
Sitting at the top of the hypothalamic-pituitary-gonadal (HPG) axis, gonadotropin releasing 
hormone (GnRH; also known as luteinising hormone releasing hormone [LHRH]) neurons are 
master regulators of the neuroendocrine control of reproduction. GnRH-secreting neurons 
originate in the nasal placode. During prenatal development their cell bodies migrate to the 
hypothalamic preoptic area (POA) and organum vasculosum laminae terminalis (OVLT). 
GnRH neurons project to the median eminence where they secrete GnRH into the 
hypophyseal portal circulation. GnRH acts at receptors on gonadotroph cells in the pituitary 
which secrete luteinising hormone (LH) or follicle stimulating hormone (FSH) depending on 
the pulsatile pattern of GnRH release. Appropriate pulsatile release of these hormones is 
essential for the initiation and maintenance of reproductive function. These hormones act 
on the gonads which in turn release their own hormones which provide negative feedback 
to the hypothalamus, completing the axis.  
 
Synchronised GnRH neuronal firing has been seen in vitro and is proposed to be essential for 
the pulsatile GnRH secretion required for LH release (85). In vivo, GnRH neurons are 
intermingled with other hypothalamic cells and therefore direct gap junctional connection 
between neighbouring GnRH neurons is unlikely. This raises the possibility that perhaps 
synchrony arises from gap junctions between GnRH neurons and astrocytes, which have 
been reported to be formed of connexin (Cx) 43, 26 and 32 proteins (86). Indeed, oestrogen 
and/or progesterone administration increases the amount of Cx43 in the POA of female but 
not male rats suggesting sexually dimorphic function of astrocyte gap junctions (87). The 
premise that astrocytes may be key players in the coordination of GnRH neuron synchrony is 
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supported by recent data indicating that GFAP, Cx43 and GnRH closely associate in the 
mouse median eminence. In addition, in cultured embryonic mouse nasal placode explants, 
pharmacological Cx43 gap junction blockade reduces both GnRH neuron synchronicity and 
GnRH secretion (88). Furthermore, female Cx43+/- mice show altered reproductive 
behaviour and disrupted oestrus cycles, providing indirect in vivo evidence for a potential 
role of astrocyte-neuronal communication in the regulation of reproductive function (87).  
 
In addition to connexins, other mediators of neural cell interaction have been implicated in 
regulating activity of GnRH neurons. Polysialylated neural cell adhesion molecule (PSA-
NCAM) promotes cell movement by hindering cell adhesion and has been investigated in 
relation to the structural plasticity of GnRH neurons. Removing the PSA from NCAM in the 
median eminence of cycling female rats appears to alter the structural interaction between 
astrocytes (GFAP-immunoreactivity) and GnRH neurons (GnRH-immunoreactivity) (89); 
however, this study did not report any disruption of the oestrus cycle in these mice, so the 
physiological impact remains unclear. Another adhesion-related protein expressed by 
hypothalamic astrocytes is receptor-like protein tyrosine phosphatase β (RPTP-β), a receptor 
which adheres to the cell adhesion molecule contactin (90). RPTP-β expression increases in 
the hypothalamus of female mice immediately prior to puberty suggesting a role for 
contactin (GnRH neurons) to RPTP-β (astrocytes) adhesion in structural plasticity (90). A 
further adhesion molecule, namely synaptic cell adhesion molecule 1 (SynCAM1), has been 
implicated in structural plasticity relating to reproductive function. This protein is found in 
GnRH neurons and hypothalamic astrocytes. The adhesive activity and expression of 
SynCAM1 in hypothalamic astrocytes is positively regulated by epidermal growth factor B4 
(erbB4) receptor signalling (91, 92). Female mice engineered to express a dominant-
negative form of SynCAM-1 in astrocytes exhibit delayed vaginal opening and first oestrus, 
reduced litter size and a disrupted oestrus cycle (91). This suggests astrocytic SynCAM1 
mediated structural plasticity is critical for correct reproductive function. Importantly, 
immunofluorescence and electron microscopy of post-mortem human female brain tissue 
shows that the close anatomical association between GnRH neurons and astrocytes is 
preserved across species (93). 
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In support of a potential role for astrocytes in the regulation of the neuroendocrine control 
of reproduction, astrocytes are directly responsive to changes in the reproductive cycle. 
Astrocytes cultured from rat hypothalami express oestrogen receptors and show an 
increase in intracellular Ca2+ and progesterone synthesis in response to oestradiol 
suggesting they may be involved in integrating hormonal feedback from the gonads (94). 
Astrocytes in the OVLT and POA of young female rats show diurnal changes in morphology 
on proestrus (the first day of the rodent oestrus cycle); a phenomenon exclusively seen in 
astrocytes that closely appose GnRH neurons (95). Astrocytes express VAPC2 (Vasoactive 
intestinal peptide receptor 2), and the diurnal component of these morphological changes is 
lost when vasoactive intestinal peptide (VIP) is knocked down from the suprachiasmatic 
nucleus (96). While the function of these changes in astrocyte morphology is not yet clear, it 
suggests they may be critical in regulating the ability of GnRH neurons to stimulate the 
proestrus LH surge. 
 
As well as enabling structural reorganisation of neurons, astrocytes can modulate neuronal 
function by the release of gliotransmitters. One gliotransmitter identified to act on GnRH 
neurons is prostaglandin E2 (PGE2) (97). PGE2 directly increases the firing rate of GnRH 
neurons in mice regardless of sex or oestrus stage, an effect blocked by a prostaglandin E2 
receptor 2 (EP2R) antagonist. Furthermore, inhibition of astrocytes with the metabolic 
inhibitor fluorocitrate decreases spontaneous GnRH neuron firing without reducing the 
response to exogenous PGE2, suggesting astrocytes are the source of PGE2 (98). Neuregulin 
(NRG) induces PGE2 release via activation of astroglial epidermal growth factor B4 (erbB4) 
receptors which may promote GnRH secretion. In vivo expression of dominant-negative 
erbB4 receptors in mouse astrocytes (GFAP-DN-erbB4 mice) attenuates the infantile LH 
surge and delays the onset of puberty in female mice (99). ErbB4-meditated PGE2 release 
from astrocytes provides excitatory drive to GnRH neurons which may explain the effects of 
deletion on reproduction (98). Expression of a mutant epidermal growth factor B1 (erbB1) 
receptor in astrocytes whose intracellular domain is non-functional also causes reproductive 
dysfunction: irregular oestrus cycles and a reduced proestrus LH surge (100), but it is unclear 
if this effect is due to decreased PGE2 release. Oxytocin, a hormone critical for the initiation 
of female puberty, acts at oxytocin receptors on hypothalamic astrocytes to stimulate PGE2 
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release and subsequent GnRH secretion (101). A second hormone, namely insulin, also acts 
directly on astrocytes and deletion of insulin receptors from astrocytes causes reproductive 
dysfunction in mice. Astrocytes in these animals show lower levels of PGE2 than wild-type 
controls suggesting insulin acts on hypothalamic astrocytes to stimulate GnRH neurons via 
PGE2 gliotransmission (102). PGE2 also negatively regulates synaptic input to GnRH neurons 
in an activity dependent manner suggesting astrocytes can decrease GnRH neuronal firing 
(103). Taken together this work shows that PGE2 release from hypothalamic astrocytes 
downstream of numerous receptors is important for stimulating GnRH neuron activity and, 
in turn, normal reproductive function. 
 
In addition to active transmitter release, astrocytes appear to play a critical role mediating 
peripubertal changes in synaptic glutamate recycling. In the hypothalami of first proestrus 
rats (compared to juvenile rats), the glutamate synthesis enzyme glutamate dehydrogenase 
(GDH) is increased while the glutamate metabolic enzyme glutamine synthetase (GS) is 
decreased (104). This suggests that at first proestrus the hypothalamus is biased towards 
producing more glutamate which may provide excitatory drive to GnRH neurons for the first 
LH surge.  
 
In summary, astrocytes in the vicinity of GnRH neurons are indispensable for normal 
reproductive function since many loss-of-function manipulations result in reproductive 
deficits. Astrocytes may impact secretion from GnRH neurons by regulating synchronisation 
via gap junctions, structural remodelling, release of gliotransmitters, and control of 
glutamate recycling. As such astrocytes can be considered core element of the HPG axis. A 
schematic summary of the current understanding of how astrocytes may impact the 
function of the HPG axis can be found in Figure 4. 
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Oxytocin neurons 
A second hypothalamic population relevant to neuroendocrine control of reproduction are 
the magnocellular oxytocin neurons of the supraoptic nucleus (SON). These neurons secrete 
the hormone oxytocin into the bloodstream to drive lactation and parturition through 
actions at the breast and uterus respectively. In rats, astrocytes neighbouring oxytocin 
neurons show a dramatic morphological change, characterised by retraction of processes, 
during times of high oxytocin secretion such as lactation (105, 106). This increases 
glutamate availability, presumably because astrocyte processes are not nearby to facilitate 
reuptake (107). This increase in glutamate availability in the synaptic cleft in turn reduces 
synaptic input to oxytocin neurons by activating presynaptic metabotropic glutamate 
receptors (mGluRs), which reduce neurotransmitter release (107). This retraction of 
astrocyte processes also decreases the availability of D-serine, a glial derived co-agonist of 
the NMDA receptor, thus impairing glutamatergic plasticity (108). However, the essential 
nature of astrocytic remodelling in the regulation of lactation is questioned by data 
indicating that inhibiting this glial remodelling by improving cell-cell adhesion in vivo in 
lactating rats does not produce an abnormal lactation phenotype nor does it disrupt the 
burst firing of magnocellular neurons characteristic of a lactation signal (109). Thus, 
astrocytes in apposition to SON oxytocin neurons act to restrict glutamate release and 
NMDA-receptor activation during lactation, but the functional contribution of these changes 
remains unclear. 
 
Astrocytes and the neuroendocrine regulation of fluid homeostasis 
Arginine Vasopressin (AVP) maintains fluid homeostasis by binding to vasopressin 2 
receptors (V2Rs) in the kidney, increasing reabsorption of water back into the blood. AVP is 
synthesised and secreted from neurons that are found primarily in the paraventricular 
(PVN), SON and suprachiasmatic (SCN) nuclei of the hypothalamus (110). Magnocellular PVN 
AVP neurons project to the posterior pituitary gland where AVP is released into the blood or 
diffusely from dendrites into the hypothalamus through Ca2+ dependent exocytosis.  
Parvocellular PVN neurons, which project to the median eminence, also produce AVP and 
modulate activity of corticotropes in the anterior pituitary, thus contributing to the 
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regulation of the hypothalamic-pituitary-adrenal (HPA) axis, which will be discussed in more 
detail later in this review. AVP is released in response to hyperosmotic stress, with 
rehydration reducing AVP release. Hypothalamic glutamate concentrations increase during 
hyperosmotic stress, stimulating SON AVP neurons to fire in a phasic manner leading to AVP 
release (111-113).  
 
Astrocytes show morphological changes in response to alterations in fluid homeostasis: 
dehydration reduces GFAP-immunoreactivity in the rodent SON and ventral glial limitans 
(114-116). Furthermore, in vitro AVP increases astrocytic volume (117, 118). In rats, 
immunoreactivity for c-Fos in the SON, in response to hyperosmotic stress, increases in 
astrocytes before neurons (119, 120), indicating that astrocytes may be early sensors of 
dehydration. This is further supported by a study indicating that pharmacological blockade 
of the gap-junction protein Cx43 prevents osmotic activation of neuronal, but not astrocytic 
c-Fos, whereas the glial metabolic inhibitor fluorocitrate attenuates c-Fos expression in both 
neurons and astrocytes (120). Together these data support a critical role for astrocytes in 
the physiological response to changes in osmolarity.  
 
AVP receptors are expressed on astrocytes (121, 122). Activation of V1bRs and V3Rs by AVP 
in primary rodent astrocytes in vitro results in Ca2+ release from intracellular stores, whereas 
activation of V1aRs leads to increased Ca2+ uptake from the extracellular space (123). Both 
mechanisms result in increased glutamate release from astrocytes, resulting in increased 
extracellular glutamate concentration (122, 123). Although these studies were conducted in 
primary rodent astrocytes derived from the cortex and hippocampus, if hypothalamic 
astrocytes display a similar response, then this increased glutamate availability may be a 
mechanism by which AVP action on astrocytes modulates neurotransmission. 
 
There is further evidence that astrocytes can impact fluid homeostasis by impacting 
neuronal firing. In vitro AVP increases monocarboxylate transporter (MCT) expression on 
primary rat astrocytes, increasing lactate release (124), which may increase availability of 
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lactate as a neuronal fuel source; thus, impacting neuronal firing. In the SON, the amino acid 
taurine is released during hypo-osmotic cell swelling, reducing firing of AVP neurons via 
direct binding to glycine receptors (125, 126). This hypo-osmotic regulation of taurine 
release in the SON is almost completely blocked by glial metabolic inhibitor fluorocitrate, 
but not by neurotoxic levels of NMDA (126, 127), suggesting that that this effect is glial 
dependent. Within the SON there is also evidence to suggest that astrocytes can modulate 
GABAergic synaptic inputs via endocannabinoid signalling (128).   
 
Intriguingly, within the PVN the orexigenic hormone ghrelin can directly stimulate firing of 
AVP neurons, inducing release of AVP which in turn induces ATP release from astrocytes. 
This subsequently impacts PVN AVP neurons by modulating presynaptic excitatory 
GABAergic inputs on to these cells (129). These data provide evidence of glial modulation of 
the activity of PVN AVP neurons and a novel link between the regulation of energy and fluid 
homeostasis. 
 
In addition to AVP pathway, the renin-angiotensin system is another key player in the 
neuroendocrine control of fluid homeostasis. Angiotensin II (AngII) is synthesised during 
dehydration and in response low blood pressure and mediating its physiological effects in 
this system via type-1 angiotensin II receptors (AT1-Rs) (130). AngII activates neurons in the 
subfornical organ (SFO), PVN, and SON, to promote hydration and AVP release (131-133).  
AT1-R are expressed on both neurons and astrocytes, with both cell types displaying 
increases Ca2+ signalling in response to AngII treatment (134, 135). In rats, AVP release and 
sodium intake in response to AngII treatment are blocked by the glial metabolic inhibitor 
fluorocitrate, indicating that glia may play a key role in AngII/AVP signalling (136). Decreased 
activity of hypothalamic GLT-1, a glutamate transporter selectively expressed in astrocytes, 
following AngII treatment has been implicated in increasing activity of PVN neurons and 
enhancing sympathetic outflow (137). Together these data suggest AngII action via on 
astrocytes may help to re-establish fluid homeostasis after low blood pressure. 
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In summary, astrocytes contribute to the regulation of fluid homeostasis via modulation of 
AVP and renin-angiotensin signalling in the CNS.  This appears to be mediated, in part, by 
direct hormone action on astrocytes. Astrocytes regulate activity of neurons in the PVN and 
SON by modulating release of gliotransmitters, regulating neurotransmitter availability in 
the synaptic cleft, and by ensheathment of neurons which is highly plastic dependent on 
physiological state. A schematic summary of the current understanding of how astrocytes 
may impact the neuroendocrine regulation of fluid homeostasis can be found in Figure 5. 
 
Astrocytes and the neuroendocrine regulation of the stress response: Hypothalamic-
pituitary-adrenal axis 
The hypothalamic-pituitary-adrenal (HPA) axis is a key neuroendocrine feedback loop 
regulating the organismal response to stress, encompassing both psychological and 
physiological stressors. Parvocellular corticotropin-releasing hormone (CRH) and AVP 
neurons in the hypothalamic PVN project to the median eminence; where CRH and 
vasopressin are released and transported to the anterior pituitary. There they act 
synergistically to promote secretion of adrenocorticotropin-releasing hormone (ACTH) from 
corticotropes. ACTH is then taken up into the blood and in turn acts on the adrenal medulla 
to promote secretion of cortisol (corticosterone in rodents). Cortisol - acting via the 
glucocorticoid receptor - provides negative feedback inhibition on the production of ACTH 
and CRH, by acting on corticotropes and parvocellular PVN neurons respectively. 
Amplification of HPA-axis activity is provided by adrenaline and noradrenaline release from 
the adrenal gland in response to activation of the sympathetic nervous system.  
 
Astrocytes, in common with a variety of neural cells, express glucocorticoid and 
mineralocorticoid receptors (138, 139) and are direct targets of glucocorticoid action. 
Recent transcriptional analysis indicates that 381 genes are regulated by dexamethasone 
treatment (a synthetic glucocorticoid) of primary mouse astrocytes (140). Both acute and 
chronic treatment of mice with corticosterone causes regulation of astrocyte-associated 
gene expression, reinforcing evidence from in vitro studies indicating that astrocytes are 
directly regulated by glucocorticoids. However, in the case of the in vivo studies the impact 
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is likely a combination of direct (action on astrocytic-glucocorticoid receptors) and indirect 
effects (action via glucocorticoid receptors on other neural cells, including neurons, which 
subsequently impact astrocyte activity) (141).    
 
Functional in vitro and in vivo studies support direct glucocorticoid mediated alterations in 
astrocyte signalling and morphology. In vitro, glucocorticoid treatment induces rapid 
increases astrocyte Ca2+ signalling (142) suggestive of an activation of non-genomic 
pathways downstream of glucocorticoid receptors. Glucocorticoid treatment of astrocytes 
in culture also enhances neuropeptide (ANP) release from astrocytes, promotes glutamate 
recycling, and leads to increases in GFAP-immunoreactivity and rearrangement of F-actin 
fibres, indicative of cellular stress (143, 144). In contrast, chronic treatment of primary 
astrocytes in culture with glucocorticoids reduces cellular proliferation and glucocorticoid 
receptor expression (145, 146). This is recapitulated in an in vivo rodent model where 
astrocyte number is reduced in the frontal cortex by chronic HPA-axis activation through 
ACTH administration (145) or in response to chronic corticosterone treatment, with or 
without additional behavioural stress (147, 148). It has been proposed that astrocytes are 
critical players in the regulation the neurogenesis during stress (149), a phenomenon which 
may underlie subsequent behavioural adaptations. Importantly, in line with sex differences 
in the response to stress at the organismal level (150) the response of astrocytes to stress is 
also sexually dimorphic, which may reflect the intersection of multiple hormonal signalling 
pathways at the level of the astrocyte (151). 
Although not directly studied in this setting, of potential significance for regulation of HPA-
axis function, astrocytes are also directly responsive to noradrenaline via receptors 
expressed on their surface (152). Noradrenaline impacts Ca2+ signalling and cellular 
metabolism in astrocytes (153-155). Neurophysiological studies indicate that within the PVN 
noradrenaline stimulates ATP release from glia which acts via P2X7 receptor mediated 
enhancement of cell surface AMPA receptor expression, to enhance glutamatergic tone 
(156). As such, astrocytes may mediate adrenaline/noradrenaline mediated positive 
feedback within the HPA-axis. In the context of the regulation of learning and memory, 
astrocytes have been implicated in mediating some of the effects of the noradrenaline 
system on this aspect of behaviour (157). 
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In summary, stress impacts numerous aspects of physiology and behaviour. The potential 
role of glia in modulating the stress-associated changes in learning and memory have 
recently been reviewed elsewhere (158). While undoubtedly important players in mediating 
the response to stress, it remains to be fully clarified whether astrocytes form part of the 
negative feedback loop that regulates HPA-axis function by directly modulating activity of 
PVN CRH or AVP neurons. However, given the evidence of astrocytic involvement in 
regulation of PVN magnocellular AVP neuronal activity in the context of osmotic stress (128, 
129) it seems highly likely. 
 
Astrocytes and the regulation of circadian rhythms 
To maximise survival most mammals time their peak activity to the presence (diurnal 
mammals) or absence (nocturnal mammals) of daylight, as appropriate. An internal master 
clock in the SCN receives information regarding light-dark cycles and uses this to entrain the 
rest of the body to a roughly 24-hour rhythm (159, 160). The ‘hands’ of the clock are 
formed through a molecular transcription-translation negative feedback loop (161). This 
loop involves many gene and protein interactions; the coordinated activity of CLOCK and 
brain and muscle aryl hydrocarbon receptor nuclear translocation factor–like protein 1 
(BMAL1) to produce PERIOD (PER) and CRYPTOCHROME (CRY) proteins being essential. PER 
and CRY subsequently inhibit the transcriptional activity of CLOCK/BMAL1, which leads to 
degradation of PER and CRY, and so restarts the cycle. These clock genes are evolutionarily 
conserved throughout the animal kingdom, though different homologs exist across 
species. Found in most mammalian organs, these genes enable cell autonomous rhythmicity 
that may diverge from that of the SCN (160). Rhythmic expression of clock genes has been 
identified in astrocytes of the SCN, but how they contribute to circadian regulation is still 
being fully elucidated.  
 
An abnormal light-dark cycle has a negative impact on health and can cause predisposition 
to health problems (162). Exposure to constant light or dark alters the expression of GFAP in 
the SCN, with an increased number of GFAP-immunoreactive cells observed in mice reared 
in constant light. Conversely, mice reared in constant dark conditions have a reduction in 
GFAP-immunoreactive cells in the SCN (163). Comparable observations have been made in 
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rats and hamsters (164-166). This suggests that astrocytes are regulated by changes in the 
light-dark cycle.  
 
In addition to being responsive to changes in the light-cycle, the activity of SCN neurons can 
impact astrocytes. Vasoactive intestinal peptide (VIP), one of the key SCN expressed 
neuropeptides, can entrain the rhythmic expression of Per2 in cultured astrocytes (167). 
Furthermore, GFAP-immunoreactive fibre coverage of VIP neurons are light dependent; 
with increased coverage during the dark phase/circadian night (168). Taken together, 
these data highlight the complexity of bidirectional control of astrocyte-neuron 
communication in the SCN. 
 
Astrocytes are emerging as important controllers of the SCN circadian clock. 
Rhythmic expression of Bmal1 in astrocytes is important in regulating behaviour and 
cognition in mice. Inducible-deletion of Bmal1 from GLAST-positive astrocytes in mice 
results in altered locomotion, as well as reduced cognitive ability in a novel object 
recognition task (169). This appears to be mediated in part by alterations in SCN VIP-
immunoreactivity and disruption of the rhythmic expression of Per2 and Bmal1 in the 
hippocampus and cortex, demonstrating the importance of astrocytes in regulating 
circadian rhythms. Of note, in the animals with inducible-deletion of Bmal1 in GLAST-
positive cells, the percentage of non-astrocyte cells in the SCN expressing Bmal1-
immunoreactivity was also reduced. This suggests that loss of Bmal1 in GLAST-positive cells 
impacted cellular expression of this key circadian regulatory gene more widely (169). In 
vitro, knockdown of Bmal1 mRNA in astrocytes that are co-cultured with neurons is 
sufficient to impact the rhythmicity of the neuronal expression of clock genes 
(169). Furthermore, an independent study published contemporaneously demonstrated 
that knockdown Bmal1 expression specifically from SCN astrocytes in mice lengthens the 
circadian period, reflected through altered locomotor activity, and impacts SCN clock gene 
expression (170). Collectively, these studies suggest that astrocytic expression of Bmal1 is 
essential for normal circadian function. 
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The molecular mechanisms by which astrocytes interact with neurons to impact circadian 
rhythms are beginning to be elucidated. Ca2+ imaging in cultured SCN slices from the mouse 
has identified anti-phasic circadian rhythms of Ca2+ oscillations between neurons and 
astrocytes, with astrocytes showing peak activity during the circadian night and neurons the 
circadian day (171). This is suggestive of a reciprocal activity relationship between the two 
cell types. Most neurons in the SCN are GABAergic (172), as such GABA as the key 
neurotransmitter regulating pacemaker activity in the SCN (173). In vitro, pharmacological 
inhibition of GABAA receptors in neuron-astrocyte co-cultures is sufficient to prevent 
astrocyte-induced entrainment of key circadian genes in neurons, including Per2 (169), 
suggesting that GABAergic signalling is critical for astrocytic regulation of neuronal circadian 
function. This in vitro evidence is supported by the finding that mice with global inducible 
knock-out of Bmal1 in astrocytes display reduced SCN GABA transporter expression and 
increased cerebrospinal fluid concentrations of GABA, implicating dysregulation of GABA 
clearance from the extracellular space in the altered circadian phenotype of these animals 
(169). Indeed, administration of a GABAA receptor antagonist rescues the dysregulated 
circadian activity pattern and cognitive deficits in these animals.  
 
Emerging research also supports astrocytic modulation of glutamatergic input as being 
critical in regulating SCN neurons. Extracellular glutamate levels in the SCN exhibit a 
circadian pattern, aligned to that of astrocytic Ca2+ signalling (171). The activity of 
glutamine synthetase (GS) is also circadian-dependent (174) and glutamate uptake is 
considerably hindered in astrocytes cultured from Clock and Per2 deficient mice (175), 
further supporting a key role for glutamatergic signalling in the regulation of the SCN clock. 
Brancaccio and colleagues have developed a model for how astrocytic release of glutamate 
during the circadian night enhances GABAergic tone in SCN neurons; thus, contributing to 
inhibition of the circuit during that time period and explaining the anti-phasic circadian 
activity of SCN astrocytes and neurons (171). 
 
In vivo evidence supports a key role for astrocytes in control of SCN periodicity. Floxed CK1εtau/tau 
mice display a 20h wheel-running activity pattern rhythm in constant darkness. CRE-mediated 
deletion of CK1εtau/tau specifically from SCN astrocytes is sufficient to restore the behavioural activity 
in these mice to a 24-hour pattern (171); thus, indicating that astrocytes can impact the intrinsic 
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activity of the SCN master clock. Indeed, even in the absence of a viable circadian clock (Cry1/2-null 
mice) reintroduction of Cry1 to SCN GFAP-expressing astrocytes is enough to enable mice to develop 
an intrinsic rhythmical pattern of behaviour even when maintained in constant darkness (176). This 
is mediated, at least in part, via astrocyte-driven glutamatergic regulation of SCN neuronal activity 
(176). These seminal studies indicate that SCN astrocyte-communication plays a prominent role in 
maintaining circadian function. A schematic summary of the current understanding of how 
astrocytes may impact the control of circadian rhythms by the SCN can be found in Figure 6. 
 
Summary and conclusions 
Astrocytes play a fundamental role in monitoring and responding to changes in hormones 
and nutrients as they penetrate the brain or are released locally. The structural apposition 
of astrocytes to both cerebral blood vessels (together with pericytes) and neurons allows 
coupling of these cues to changes in the activity of astrocytes and subsequently neurons. 
Over the past decade or so, the generation of astrocyte-specific genetic manipulations in 
mice has permitted the assessment of glial roles in regulating whole body physiology, 
including (but not limited to) regulation of food intake, glucose homeostasis, reproduction, 
fluid balance, breathing and blood pressure regulation. Emerging technological 
advancements permitting more spatially and temporally-targeted manipulation of 
astrocytes will enable previously unknown astrocyte functions to be described. Going 
forward, better classification of astrocytes into specific subtypes, akin to those of neurons 
(i.e. glutamatergic and GABAergic neurons) is fundamentally required and will allow yet 
more detailed examination of the astrocyte contribution to neuroendocrine function. This 
will clearly be challenging given that astrocytes are highly plastic cells, reacting and adapting 
to new physiological and pathophysiological environments. Importantly, assessment of 
astrocyte function and the gliotransmitters they release (and their receptors) may expose 
potential therapeutic targets for treatment of significant public health challenges including 
obesity, diabetes and endocrine disorders such as hypothyroidism and hypogonadism. 
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Figure Legends 
Figure 1: Schematic overview of the proposed mechanisms by which astrocytes can impact 
neuroendocrine systems. (1) As a key component of the blood-brain barrier (BBB), 
astrocytes may impact entry of circulating factors, including hormones and nutrients in to 
the CNS. (2) Like neurons, astrocytes are direct targets of hormone action in the CNS via 
receptors expressed on their surface. (3) Astrocytes are a source of bioactive signalling 
molecules including gliotransmitters, and neurosteroids. Astrocytes also regulate 
neurotransmitter availability in the synaptic cleft through reuptake and recycling of 
neurotransmitters. (4) Morphological changes in astrocytes results in ensheathment of 
synapses which impacts synapse stability and extra-synaptic communication. 
 
Figure 2: Simplified schematic summary of mechanisms by which hypothalamic astrocytes 
regulate neuroendocrine control of feeding. (1) Astrocytes of the hypothalamus express 
receptors for key homeostatic hormones, including leptin and ghrelin; (2) Deletion of leptin 
receptors and changes in diet alter the synaptic ensheathment of neighbouring neurons 
which control feeding; (3) Chronic leptin or ghrelin administration, and changes in food 
intake, change the expression of glial glutamate and glucose transporters in the medial basal 
hypothalamus; (4) Hypothalamic astrocytes show inflammatory responses and 
morphological plasticity in response to intake of a high-fat diet and manipulation of these 
inflammatory pathways (namely the NF-κb pathway) in astrocytes modulates feeding and 
can be protective against diet-induced obesity. 
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Figure 3: Simplified schematic summary of mechanisms by which astrocytes regulate 
glucose homeostasis. (1) Astrocytes express glucose transporter (GLUT) 1 and 2 and their 
expression is involved in stimulating the counterregulatory response (CRR) to 
hypoglycaemia; (2) Reduced expression of glial glutamate transporters after recurrent 
hypoglycaemia disrupts glutamatergic neurotransmission necessary for the appropriate 
CRR; (3) Astrocytes store glycogen and use this to provide fuel to neurons during glucose 
deprivation, however glycogen supercompenstation following recurrent hypoglycaemia may 
blunt the CRR; (4) Inflammation and astrogliosis are observed in mouse models of diabetes 
and modulation of astrocyte NF-κB signalling is protective against diet-induced glucose 
intolerance; (5) By releasing gliotransmitters, altering physical contact, and reuptake of 
neurotransmitters, astrocytes modulate neurons in the brainstem and hypothalamus to 
control neuronal responses to changes in glucose availability. 
Figure 4: Simplified schematic summary of mechanisms by which hypothalamic astrocytes 
regulate neuroendocrine control of reproduction. (1) Astrocytes of the hypothalamus 
express receptors for numerous neuropeptides and hormones including oestradiol, 
vasoactive intestinal polypeptide (VIP), neuregulin, and oxytocin; (2) Stimulation of certain 
receptors on astrocytes (namely epidermal growth factor B4 [erbB4], oxytocin, and insulin 
receptors) leads to release of prostaglandin E2 (PGE2) which acts on prostaglandin E2 
receptor 2 (EP2R) on GnRH neurons to increase firing and GnRH secretion; (3) Astrocytes are 
responsible for the reuptake and synthesis of glutamate and the levels of proteins required 
for this process vary throughout reproductive maturation; (4) Gap junction connections 
between astrocytes and GnRH neurons may allow for synchronous firing and hormone 
release between spatially separated neurons. The net effect of these mechanisms is to 
modulate GnRH secretion, a master regulator of reproductive function. 
Figure 5: Simplified schematic summary of mechanisms by which astrocytes modulate the 
neuroendocrine regulation of fluid homeostasis. (1) Astrocytes in the hypothalamus 
express receptors for arginine vasopressin (AVP; V3R, V1aR, and V1bR) and angiotensin II 
(AngII; AT1R). During hyperosmotic events, AVP and AngII activate intracellular signalling 
pathways in astrocytes which increase intracellular Ca2+; (2) Increases in intracellular Ca2+ 
lead to increased glutamate release from astrocyte which may act on neurons to drive 
phasic firing and AVP release; (3) Taurine is released from astrocytes under hypo-osmotic 
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stress which can inhibit AVP neurons by activating neuronal glycine receptors; (4) Astrocytes 
of the supraoptic nucleus show morphological changes and c-FOS expression in response to 
dehydration and in vitro astrocytes swell in response to hypo-osmotic stress. Thus, 
astrocytes can sense and respond to changes in fluid homeostasis. 
Figure 6: Simplified schematic summary of mechanisms by which hypothalamic astrocytes 
regulate the circadian ‘master’ clock of the suprachiasmatic nucleus. The suprachiasmatic 
nucleus (SCN) within the hypothalamus is responsible for entraining daily rhythms to the 
light-dark cycle. (A) Within the SCN, astrocytes have rhythmic oscillations in Ca2+ anti-phasic 
with those seen in neurons: astrocytes showing peak activity during the circadian night and 
neurons the circadian day. (B) Within SCN the bi-directional communication between 
neurons and astrocytes is important for maintaining integrity of the master circadian clock: 
(1) Astrocytic recycling of glutamate and GABA contributes to regulation of SCN neuron 
activity; (2) Vasoactive intestinal peptide (VIP), a key neuropeptide transmitter in the SCN, 
can entrain rhymical expression of ‘circadian clock genes’ in astrocytes; (3) Astrocyte 
ensheathment of SCN VIP neurons is light dependent, with increased coverage during the 
circadian night. 
 
References 
1. Ebling FJP, Lewis JE. Tanycytes and hypothalamic control of energy metabolism. Glia. 2018; 
66(6): 1176-84. 
2. Lewis JE, Ebling FJ. Tanycytes As Regulators of Seasonal Cycles in Neuroendocrine Function. 
Front Neurol. 2017; 879. 
3. Rosso L, Mienville JM. Pituicyte modulation of neurohormone output. Glia. 2009; 57(3): 235-
43. 
4. Verkhratsky A, Nedergaard M. Physiology of Astroglia. Physiol Rev. 2018; 98(1): 239-389. 
5. Banker GA. Trophic interactions between astroglial cells and hippocampal neurons in 
culture. Science. 1980; 209(4458): 809-10. 
6. Allen NJ, Bennett ML, Foo LC, Wang GX, Chakraborty C, Smith SJ, Barres BA. Astrocyte 
glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. Nature. 
2012; 486(7403): 410-4. 
7. Christopherson KS, Ullian EM, Stokes CC, Mullowney CE, Hell JW, Agah A, Lawler J, Mosher 
DF, Bornstein P, Barres BA. Thrombospondins are astrocyte-secreted proteins that promote CNS 
synaptogenesis. Cell. 2005; 120(3): 421-33. 
8. Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung J, Foo LC, 
Thompson A, Chen C, Smith SJ, Barres BA. Astrocytes mediate synapse elimination through MEGF10 
and MERTK pathways. Nature. 2013; 504(7480): 394-400. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
9. Kucukdereli H, Allen NJ, Lee AT, Feng A, Ozlu MI, Conatser LM, Chakraborty C, Workman G, 
Weaver M, Sage EH, Barres BA, Eroglu C. Control of excitatory CNS synaptogenesis by astrocyte-
secreted proteins Hevin and SPARC. Proc Natl Acad Sci U S A. 2011; 108(32): E440-9. 
10. Farmer WT, Murai K. Resolving Astrocyte Heterogeneity in the CNS. Front Cell Neurosci. 
2017; 11300. 
11. Xin W, Bonci A. Functional Astrocyte Heterogeneity and Implications for Their Role in 
Shaping Neurotransmission. Front Cell Neurosci. 2018; 12141. 
12. Molofsky AV, Deneen B. Astrocyte development: A Guide for the Perplexed. Glia. 2015; 
63(8): 1320-9. 
13. Boisvert MM, Erikson GA, Shokhirev MN, Allen NJ. The Aging Astrocyte Transcriptome from 
Multiple Regions of the Mouse Brain. Cell Rep. 2018; 22(1): 269-85. 
14. Burda JE, Sofroniew MV. Reactive gliosis and the multicellular response to CNS damage and 
disease. Neuron. 2014; 81(2): 229-48. 
15. Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 2015; 16(5): 
249-63. 
16. Morizawa YM, Hirayama Y, Ohno N, Shibata S, Shigetomi E, Sui Y, Nabekura J, Sato K, 
Okajima F, Takebayashi H, Okano H, Koizumi S. Reactive astrocytes function as phagocytes after 
brain ischemia via ABCA1-mediated pathway. Nat Commun. 2017; 8(1): 28. 
17. Clarke LE, Liddelow SA, Chakraborty C, Munch AE, Heiman M, Barres BA. Normal aging 
induces A1-like astrocyte reactivity. Proc Natl Acad Sci U S A. 2018; 115(8): E1896-E905. 
18. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, Bennett ML, 
Munch AE, Chung WS, Peterson TC, Wilton DK, Frouin A, Napier BA, Panicker N, Kumar M, 
Buckwalter MS, Rowitch DH, Dawson VL, Dawson TM, Stevens B, Barres BA. Neurotoxic reactive 
astrocytes are induced by activated microglia. Nature. 2017; 541(7638): 481-7. 
19. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA. Genomic analysis of 
reactive astrogliosis. J Neurosci. 2012; 32(18): 6391-410. 
20. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, Gordon S, Hamilton JA, 
Ivashkiv LB, Lawrence T, Locati M, Mantovani A, Martinez FO, Mege JL, Mosser DM, Natoli G, Saeij 
JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van Ginderachter JA, Vogel SN, Wynn TA. 
Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 
2014; 41(1): 14-20. 
21. Basco E, Woodhams PL, Hajos F, Balazs R. Immunocytochemical demonstration of glial 
fibrillary acidic protein in mouse tanycytes. Anat Embryol (Berl). 1981; 162(2): 217-22. 
22. Cahoy JD, Emery B, Kaushal A, Foo LC, Zamanian JL, Christopherson KS, Xing Y, Lubischer JL, 
Krieg PA, Krupenko SA, Thompson WJ, Barres BA. A transcriptome database for astrocytes, neurons, 
and oligodendrocytes: a new resource for understanding brain development and function. J 
Neurosci. 2008; 28(1): 264-78. 
23. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain 
barrier. Nat Rev Neurosci. 2006; 7(1): 41-53. 
24. De Souza CT, Araujo EP, Bordin S, Ashimine R, Zollner RL, Boschero AC, Saad MJA, Velloso LA. 
Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance 
in the hypothalamus. Endocrinology. 2005; 146(10): 4192-9. 
25. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKβ/NF-κB and ER Stress 
Link Overnutrition to Energy Imbalance and Obesity. Cell. 2008; 135(1): 61-73. 
26. Horvath TL, Sarman B, García-Cáceres C, Enriori PJ, Sotonyi P, Shanabrough M, Borok E, 
Argente J, Chowen JA, Perez-Tilve D, Pfluger PT, Brönneke HS, Levin BE, Diano S, Cowley Ma, Tschöp 
MH. Synaptic input organization of the melanocortin system predicts diet-induced hypothalamic 
reactive gliosis and obesity. Proceedings of the National Academy of Sciences of the United States of 
America. 2010; 107(33): 14875-80. 
27. Buckman LB, Thompson MM, Moreno HN, Ellacott KLJ. Regional astrogliosis in the mouse 
hypothalamus in response to obesity. Journal of Comparative Neurology. 2013; 521(6): 1322-33. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
28. Thaler J, Yi C, Schur E, Guyenet S, Hwang B, Dietrich M, Zhao X, Sarruf D, Izgur V, Maravilla K, 
Nguyen H, Fischer J, Matsen M, Wisse B, Morton G, Horvarth T, Baskin D, Tshop M, Schwartz M. 
Obesity is associated with hypothalamic injury in rodents and humans. Journal of Clinical 
Investigation. 2012; 122(1): 153-. 
29. Berkseth KE, Guyenet SJ, Melhorn SJ, Lee D, Thaler JP, Schur EA, Schwartz MW. 
Hypothalamic gliosis associated with high-fat diet feeding is reversible in mice: A combined 
immunohistochemical and magnetic resonance imaging study. Endocrinology. 2014; 155(8): 2858-
67. 
30. Zhang Y, Reichel JM, Han C, Zuniga-Hertz JP, Cai D. Astrocytic Process Plasticity and IKKβ/NF-
κB in Central Control of Blood Glucose, Blood Pressure, and Body Weight. Cell Metabolism. 2017; 
25(5): 1091-102.e4. 
31. Douglass JD, Dorfman MD, Fasnacht R, Shaffer LD, Thaler JP. Astrocyte IKKβ/NF-κB signaling 
is required for diet-induced obesity and hypothalamic inflammation. Molecular Metabolism. 2017; 
0(0): 366-73. 
32. Balland E, Cowley MA. Short-term high fat diet increases the presence of astrocytes in the 
hypothalamus of C57BL6 mice without altering leptin sensitivity. Journal of Neuroendocrinology. 
20170-3. 
33. Buckman LB, Thompson MM, Lippert RN, Blackwell TS, Yull FE, Ellacott KLJ. Evidence for a 
novel functional role of astrocytes in the acute homeostatic response to high-fat diet intake in mice. 
Molecular Metabolism. 2015; 4(1): 58-63. 
34. Chen N, Sugihara H, Kim J, Fu Z, Barak B, Sur M, Feng G, Han W. Direct modulation of GFAP-
expressing glia in the arcuate nucleus bi-directionally regulates feeding. eLife. 2016; 51-21. 
35. Fuente-Martín E, García-Cáceres C, Argente-Arizón P, Díaz F, Granado M, Freire-Regatillo A, 
Castro-González D, Ceballos ML, Frago LM, Dickson SL, Argente J, Chowen JA. Leptin Regulates 
Glucose and Glutamate Transporters in Hypothalamic Astrocytes. Journal of Clinical Investigation. 
2012; 122(11): 3900-13. 
36. Cheunsuang O, Morris R. Astrocytes in the arcuate nucleus and median eminence that take 
up a fluorescent dye from the circulation express leptin receptors and neuropeptide Y Y1 receptors. 
Glia. 2005; 52(3): 228-33. 
37. Hsuchou H, He Y, Kastin AJ, Tu H, Markadakis EN, Rogers RC, Fossier PB, Pan W. Obesity 
induces functional astrocytic leptin receptors in hypothalamus. Brain. 2009; 132(4): 889-902. 
38. Pan W, Hsuchou H, He Y, Sakharkar A, Cain C, Yu C, Kastin AJ. Astrocyte leptin receptor (ObR) 
and leptin transport in adult-onset obese mice. Endocrinology. 2008; 149(6): 2798-806. 
39. García-Cáceres C, Fuente-Martán E, Burgos-Ramos E, Granado M, Frago LM, Barrios V, 
Horvath T, Argente J, Chowen JA. Differential acute and chronic effects of leptin on hypothalamic 
astrocyte morphology and synaptic protein levels. Endocrinology. 2011; 152(5): 1809-18. 
40. Kim JG, Suyama S, Koch M, Jin S, Argente-Arizon P, Argente J, Liu Z-W, Zimmer MR, Jeong JK, 
Szigeti-Buck K, Gao Y, Garcia-Caceres C, Yi C-X, Salmaso N, Vaccarino FM, Chowen J, Diano S, Dietrich 
MO, Tschöp MH, Horvath TL. Leptin signaling in astrocytes regulates hypothalamic neuronal circuits 
and feeding. Nature Neuroscience. 2014; 17(7): 908-10. 
41. Wang Y, Hsuchou H, He Y, Kastin AJ, Pan W. Role of Astrocytes in Leptin Signaling. Journal of 
Molecular Neuroscience. 2015; 56(4): 829-39. 
42. Rottkamp DM, Rudenko IA, Maier MT, Roshanbin S, Yulyaningsih E, Perez L, Valdearcos M, 
Chua S, Koliwad SK, Xu AW. Leptin potentiates astrogenesis in the developing hypothalamus. 
Molecular Metabolism. 2015; 4(11): 881-9. 
43. Fuente-Martín E, García-Cáceres C, Argente-Arizón P, Díaz F, Granado M, Freire-Regatillo A, 
Castro-González D, Ceballos ML, Frago LM, Dickson SL, Argente J, Chowen JA. Ghrelin Regulates 
Glucose and Glutamate Transporters in Hypothalamic Astrocytes. Scientific reports. 2016; 
6(November 2015): 23673-. 
44. Baquedano E, Chowen JA, Argente J, Frago LM. Differential effects of GH and GH-releasing 
peptide-6 on astrocytes. Journal of Endocrinology. 2013; 218(3): 263-74. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
45. García-Cáceres C, Fuente-Martín E, Díaz F, Granado M, Argente-Arizón P, Frago LM, Freire-
Regatillo A, Barrios V, Argente J, Chowen JA. The opposing effects of ghrelin on hypothalamic and 
systemic inflammatory processes are modulated by its acylation status and food intake in male rats. 
Endocrinology. 2014; 155(8): 2868-80. 
46. Yang L, Qi Y, Yang Y. Astrocytes Control Food Intake by Inhibiting AGRP Neuron Activity via 
Adenosine A<inf>1</inf> Receptors. Cell Reports. 2015; 11(5): 798-807. 
47. Sweeney P, Qi Y, Xu Z, Yang Y. Activation of hypothalamic astrocytes suppresses feeding 
without altering emotional states. Glia. 20161-11. 
48. Scofield MD, Boger HA, Smith RJ, Li H, Haydon PG, Kalivas PW. Gq-DREADD selectively 
initiates glial glutamate release and inhibits cue-induced cocaine seeking. Biological Psychiatry. 
2015; 78(7): 441-51. 
49. Scofield MD, Li H, Siemsen BM, Healey KL, Tran PK, Woronoff N, Boger HA, Kalivas PW, 
Reissner KJ. Cocaine Self-Administration and Extinction Leads to Reduced Glial Fibrillary Acidic 
Protein Expression and Morphometric Features of Astrocytes in the Nucleus Accumbens Core. 
Biological Psychiatry. 2016; 80(3): 207-15. 
50. Rossi MA, Stuber GD. Overlapping Brain Circuits for Homeostatic and Hedonic Feeding. Cell 
Metabolism. 2017(2017). 
51. Reiner DJ, Mietlicki-Baase EG, McGrath LE, Zimmer DJ, Bence KK, Sousa GL, Konanur VR, 
Krawczyk J, Burk DH, Kanoski SE, Hermann GE, Rogers RC, Hayes MR. Astrocytes Regulate GLP-1 
Receptor-Mediated Effects on Energy Balance. Journal of Neuroscience. 2016; 36(12): 3531-40. 
52. Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and 
characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Molecular 
Metabolism. 2015; 4(10): 718-31. 
53. Bartolome JV, Bartolome MB, Harris EB, Pauk JS, Schanberg SM. Regulation of insulin and 
glucose plasma levels by central nervous system beta-endorphin in preweanling rats. Endocrinology. 
1989; 124(5): 2153-8. 
54. Konner AC, Janoschek R, Plum L, Jordan SD, Rother E, Ma X, Xu C, Enriori P, Hampel B, Barsh 
GS, Kahn CR, Cowley MA, Ashcroft FM, Bruning JC. Insulin action in AgRP-expressing neurons is 
required for suppression of hepatic glucose production. Cell Metab. 2007; 5(6): 438-49. 
55. Tong Q, Ye C, McCrimmon RJ, Dhillon H, Choi B, Kramer MD, Yu J, Yang Z, Christiansen LM, 
Lee CE, Choi CS, Zigman JM, Shulman GI, Sherwin RS, Elmquist JK, Lowell BB. Synaptic glutamate 
release by ventromedial hypothalamic neurons is part of the neurocircuitry that prevents 
hypoglycemia. Cell Metab. 2007; 5(5): 383-93. 
56. McDougal DH, Hermann GE, Rogers RC. Astrocytes in the nucleus of the solitary tract are 
activated by low glucose or glucoprivation: evidence for glial involvement in glucose homeostasis. 
Frontiers in Neuroscience. 2013; 7. 
57. Chowdhury GMI, Wang P, Ciardi A, Mamillapalli R, Johnson J, Zhu W, Eid T, Behar K, Chan O. 
Impaired Glutamatergic Neurotransmission in the Ventromedial Hypothalamus May Contribute to 
Defective Counterregulation in Recurrently Hypoglycemic Rats. Diabetes. 2017; 66(7): 1979-89. 
58. Marty N, Dallaporta M, Foretz M, Emery M, Tarussio D, Bady I, Binnert C, Beermann F, 
Thorens B. Regulation of glucagon secretion by glucose transporter type 2 (glut2) and astrocyte-
dependent glucose sensors. J Clin Invest. 2005; 115(12): 3545-53. 
59. García-Cáceres C, Quarta C, Varela L, Gao Y, Gruber T, Legutko B, Jastroch M, Johansson P, 
Ninkovic J, Yi CX, Le Thuc O, Szigeti-Buck K, Cai W, Meyer CW, Pfluger PT, Fernandez AM, Luquet S, 
Woods SC, Torres-Alemán I, Kahn CR, Götz M, Horvath TL, Tschöp MH. Astrocytic Insulin Signaling 
Couples Brain Glucose Uptake with Nutrient Availability. Cell. 2016; 166(4): 867-80. 
60. Chari M, Yang CS, Lam CK, Lee K, Mighiu P, Kokorovic A, Cheung GW, Lai TY, Wang PY, Lam 
TK. Glucose transporter-1 in the hypothalamic glial cells mediates glucose sensing to regulate 
glucose production in vivo. Diabetes. 2011; 60(7): 1901-6. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
61. Cataldo AM, Broadwell RD. Cytochemical identification of cerebral glycogen and glucose-6-
phosphatase activity under normal and experimental conditions. II. Choroid plexus and ependymal 
epithelia, endothelia and pericytes. J Neurocytol. 1986; 15(4): 511-24. 
62. Brown AM, Sickmann HM, Fosgerau K, Lund TM, Schousboe A, Waagepetersen HS, Ransom 
BR. Astrocyte glycogen metabolism is required for neural activity during aglycemia or intense 
stimulation in mouse white matter. J Neurosci Res. 2005; 79(1-2): 74-80. 
63. Alquier T, Kawashima J, Tsuji Y, Kahn BB. Role of hypothalamic adenosine 5'-
monophosphate-activated protein kinase in the impaired counterregulatory response induced by 
repetitive neuroglucopenia. Endocrinology. 2007; 148(3): 1367-75. 
64. Herzog RI, Chan O, Yu S, Dziura J, McNay EC, Sherwin RS. Effect of acute and recurrent 
hypoglycemia on changes in brain glycogen concentration. Endocrinology. 2008; 149(4): 1499-504. 
65. Duarte JMN, Morgenthaler FD, Gruetter R. Glycogen Supercompensation in the Rat Brain 
After Acute Hypoglycemia is Independent of Glucose Levels During Recovery. Neurochem Res. 2017; 
42(6): 1629-35. 
66. Oz G, DiNuzzo M, Kumar A, Moheet A, Khowaja A, Kubisiak K, Eberly LE, Seaquist ER. 
Cerebral glycogen in humans following acute and recurrent hypoglycemia: Implications on a role in 
hypoglycemia unawareness. J Cereb Blood Flow Metab. 2017; 37(8): 2883-93. 
67. Saravia FE, Revsin Y, Gonzalez Deniselle MC, Gonzalez SL, Roig P, Lima A, Homo-Delarche F, 
De Nicola AF. Increased astrocyte reactivity in the hippocampus of murine models of type 1 
diabetes: the nonobese diabetic (NOD) and streptozotocin-treated mice. Brain Res. 2002; 957(2): 
345-53. 
68. Afsari ZH, Renno WM, Abd-El-Basset E. Alteration of glial fibrillary acidic proteins 
immunoreactivity in astrocytes of the spinal cord diabetic rats. Anat Rec (Hoboken). 2008; 291(4): 
390-9. 
69. Garcia-Caceres C, Lechuga-Sancho A, Argente J, Frago LM, Chowen JA. Death of 
hypothalamic astrocytes in poorly controlled diabetic rats is associated with nuclear translocation of 
apoptosis inducing factor. J Neuroendocrinol. 2008; 20(12): 1348-60. 
70. Fernandez-Agullo T. Thyrotropin-releasing hormone and its receptor in glia. Glia. 2001; 
33(4): 267-76. 
71. Hartel K, Schnell C, Hulsmann S. Astrocytic calcium signals induced by neuromodulators via 
functional metabotropic receptors in the ventral respiratory group of neonatal mice. Glia. 2009; 
57(8): 815-27. 
72. McDermott AM, Dickinson SL, Wilkin GP. Thyrotropin releasing hormone (TRH) and a 
degradation stabilized analogue (RX77368) stimulate phosphoinositide turnover in cultured 
astrocytes in a regionally specific manner. Neurochem Int. 1992; 20(3): 307-13. 
73. Braun D, Kinne A, Brauer AU, Sapin R, Klein MO, Kohrle J, Wirth EK, Schweizer U. 
Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain 
and in primary brain cells. Glia. 2011; 59(3): 463-71. 
74. Wirth EK, Schweizer U, Kohrle J. Transport of thyroid hormone in brain. Front Endocrinol 
(Lausanne). 2014; 598. 
75. Guadano-Ferraz A, Obregon MJ, St Germain DL, Bernal J. The type 2 iodothyronine 
deiodinase is expressed primarily in glial cells in the neonatal rat brain. Proc Natl Acad Sci U S A. 
1997; 94(19): 10391-6. 
76. Tu HM, Kim SW, Salvatore D, Bartha T, Legradi G, Larsen PR, Lechan RM. Regional 
distribution of type 2 thyroxine deiodinase messenger ribonucleic acid in rat hypothalamus and 
pituitary and its regulation by thyroid hormone. Endocrinology. 1997; 138(8): 3359-68. 
77. Gereben B, Zavacki AM, Ribich S, Kim BW, Huang SA, Simonides WS, Zeold A, Bianco AC. 
Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008; 
29(7): 898-938. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
78. Werneck de Castro JP, Fonseca TL, Ueta CB, McAninch EA, Abdalla S, Wittmann G, Lechan 
RM, Gereben B, Bianco AC. Differences in hypothalamic type 2 deiodinase ubiquitination explain 
localized sensitivity to thyroxine. J Clin Invest. 2015; 125(2): 769-81. 
79. Fonseca TL, Correa-Medina M, Campos MP, Wittmann G, Werneck-de-Castro JP, Arrojo e 
Drigo R, Mora-Garzon M, Ueta CB, Caicedo A, Fekete C, Gereben B, Lechan RM, Bianco AC. 
Coordination of hypothalamic and pituitary T3 production regulates TSH expression. J Clin Invest. 
2013; 123(4): 1492-500. 
80. Fonseca TL, Werneck-De-Castro JP, Castillo M, Bocco BM, Fernandes GW, McAninch EA, 
Ignacio DL, Moises CC, Ferreira AR, Gereben B, Bianco AC. Tissue-specific inactivation of type 2 
deiodinase reveals multilevel control of fatty acid oxidation by thyroid hormone in the mouse. 
Diabetes. 2014; 63(5): 1594-604. 
81. Sayre NL, Sifuentes M, Holstein D, Cheng SY, Zhu X, Lechleiter JD. Stimulation of astrocyte 
fatty acid oxidation by thyroid hormone is protective against ischemic stroke-induced damage. J 
Cereb Blood Flow Metab. 2017; 37(2): 514-27. 
82. Igelhorst BA, Niederkinkhaus V, Karus C, Lange MD, Dietzel ID. Regulation of neuronal 
excitability by release of proteins from glial cells. Philos Trans R Soc Lond B Biol Sci. 2015; 370(1672). 
83. Mendes-de-Aguiar CB, Alchini R, Decker H, Alvarez-Silva M, Tasca CI, Trentin AG. Thyroid 
hormone increases astrocytic glutamate uptake and protects astrocytes and neurons against 
glutamate toxicity. J Neurosci Res. 2008; 86(14): 3117-25. 
84. Mohacsik P, Zeold A, Bianco AC, Gereben B. Thyroid hormone and the neuroglia: both 
source and target. J Thyroid Res. 2011; 2011215718. 
85. Constantin S, Caraty A, Wray S, Duittoz AH. Development of gonadotropin-releasing 
hormone-1 secretion in mouse nasal explants. Endocrinology. 2009; 150(7): 3221-7. 
86. Tsukahara S, Maekawa F, Tsukamura H, Hirunagi K, Maeda K. Morphological characterization 
of relationship between gap junctions and gonadotropin releasing hormone nerve terminals in the 
rat median eminence. Neuroscience letters. 1999; 261(1-2): 105-8. 
87. Gulinello M, Etgen AM. Sexually dimorphic hormonal regulation of the gap junction protein, 
CX43, in rats and altered female reproductive function in CX43+/- mice. Brain Research. 2005; 
1045(1-2): 107-15. 
88. Pinet-Charvet C, Geller S, Desroziers E, Ottogalli M, Lomet D, Georgelin C, Tillet Y, 
Franceschini I, Vaudin P, Duittoz A. GnRH episodic secretion is altered by pharmacological blockade 
of gap junctions: Possible involvement of glial cells. Endocrinology. 2016; 157(1): 304-22. 
89. Kumar S, Parkash J, Kataria H, Kaur G. Enzymatic removal of polysialic acid from neural cell 
adhesion molecule interrupts gonadotropin releasing hormone (GnRH) neuron-glial remodeling. 
Molecular and Cellular Endocrinology. 2012; 348(1): 95-103. 
90. Parent AS, Mungenast AE, Lomniczi A, Sandau US, Peles E, Bosch MA, Rønnekleiv OK, Ojeda 
SR. A contactin-receptor-like protein tyrosine phosphatase β complex mediates adhesive 
communication between astroglial cells and gonadotrophin-releasing hormone neurones. Journal of 
Neuroendocrinology. 2007; 19(11): 847-58. 
91. Sandau US, Mungenast AE, Alderman Z, Sardi SP, Fogel AI, Taylor B, Parent AS, Biederer T, 
Corfas G, Ojeda SR. SynCAM1, a synaptic adhesion molecule, is expressed in astrocytes and 
contributes to erbB4 receptor-mediated control of female sexual development. Endocrinology. 2011; 
152(6): 2364-76. 
92. Sandau US, Mungenast AE, McCarthy J, Biederer T, Corfas G, Ojeda SR. The synaptic cell 
adhesion molecule, SynCAM1, mediates astrocyte-to- astrocyte and astrocyte-to-GnRH neuron 
adhesiveness in the mouse hypothalamus. Endocrinology. 2011; 152(6): 2353-63. 
93. Baroncini M, Allet C, Leroy D, Beauvillain JC, Francke JP, Prevot V. Morphological evidence 
for direct interaction between gonadotrophin-releasing hormone neurones and astroglial cells in the 
human hypothalamus. Journal of Neuroendocrinology. 2007; 19(9): 691-702. 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
94. Kuo J, Hamid N, Bondar G, Prossnitz ER, Micevych P. Membrane estrogen receptors 
stimulate intracellular calcium release and progesterone sysnthesis in hypothalamic astrocytes. 
Journal of Neuroscience. 2010; 30(39): 12950-7. 
95. Cashion AB, Smith MJ, Wise PM. The morphometry of astrocytes in the rostral preoptic area 
exhibits a diurnal rhythm on proestrus: Relationship to the luteinizing hormone surge and effects of 
age. Endocrinology. 2003; 144(1): 274-80. 
96. Gerhold LM, Wise PM. Vasoactive intestinal polypeptide regulates dynamic changes in 
astrocyte morphometry: Impact on gonadotropin-releasing hormone neurons. Endocrinology. 2006; 
147(5): 2197-202. 
97. Rage F, Lee BJ, Ma YJ, Ojeda SR. Estradiol enhances prostaglandin E2 receptor gene 
expression in luteinizing hormone-releasing hormone (LHRH) neurons and facilitates the LHRH 
response to PGE2 by activating a glia-to-neuron signaling pathway. The Journal of neuroscience : the 
official journal of the Society for Neuroscience. 1997; 17(23): 9145-56. 
98. Clasadonte J, Poulain P, Hanchate NK, Corfas G, Ojeda SR, Prevot V. Prostaglandin E2 release 
from astrocytes triggers gonadotropin-releasing hormone (GnRH) neuron firing via EP2 receptor 
activation. Proceedings of the National Academy of Sciences. 2011; 108(38): 16104-9. 
99. Prevot V, Rio C, Cho GJ, Lomniczi A, Heger S, Neville CM, Rosenthal Na, Ojeda SR, Corfas G. 
Normal Female Sexual Development Requires Neuregulin – erbB Receptor Signaling in Hypothalamic 
Astrocytes. The Journal of Neuroscience. 2003; 23(1): 230-9. 
100. Li B, Yang Z, Hou J, McCracken A, Jennings MA, Ma MYJ. Compromised reproductive function 
in adult female mice selectively expressing mutant ErbB-1 tyrosine kinase receptors in astroglia. 
Molecular endocrinology (Baltimore, Md). 2003; 17(11): 2365-76. 
101. Parent AS, Rasier G, Matagne V, Lomniczi A, Lebrethon MC, Gérard A, Ojeda SR, Bourguignon 
JP. Oxytocin facilitates female sexual maturation through a glia-to-neuron signaling pathway. 
Endocrinology. 2008; 149(3): 1358-65. 
102. Manaserh IH, Chikkamenahalli L, Ravi S, Dube PR, Park JJ, Hill JW. Ablating astrocyte insulin 
receptors leads to delayed puberty and hypogonadism in mice. PLoS Biol. 2019; 17(3): e3000189. 
103. Glanowska KM, Moenter SM. Endocannabinoids and prostaglandins both contribute to 
GnRH neuron-GABAergic afferent local feedback circuits. Journal of Neurophysiology. 2011; 106(6): 
3073-81. 
104. Roth CL, McCormack AL, Lomniczi A, Mungenast AE, Ojeda SR. Quantitative proteomics 
identifies a change in glial glutamate metabolism at the time of female puberty. Molecular and 
Cellular Endocrinology. 2006; 254-25551-9. 
105. Hatton GI, Tweedle CD. Magnocellular neuropeptidergic neurons in hypothalamus: Increases 
in membrane apposition and number of specialized synapses from pregnancy to lactation. Brain 
Research Bulletin. 1982; 8(2): 197-204. 
106. Theodosis DT, Chapman DB, Montagnese C, Poulain DA, Morris JF. Structural Plasticity in the 
Hypothalamic Nucleus At Lactation Affects But Not Vasopressin-Secreting. Neuroscience. 1986; 
17(3): 661-78. 
107. Oliet SHR, Piet R, Poulain DA. Control of glutamate clearance and synaptic efficacy by glial 
coverage of neurons. Science. 2001; 292(5518): 923-6. 
108. Panatier A, Theodosis DT, Mothet JP, Touquet B, Pollegioni L, Poulain DA, Oliet SHR. Glia-
Derived d-Serine Controls NMDA Receptor Activity and Synaptic Memory. Cell. 2006; 125(4): 775-84. 
109. Catheline G, Touquet B, Lombard MC, Poulain DA, Theodosis DT. A study of the role of 
neuro-glial remodeling in the oxytocin system at lactation. Neuroscience. 2006; 137(1): 309-16. 
110. Brownstein M, Russel T, Gainer H. Synthesis, transport and release of posterior pituitary 
hormones. Science. 1980; 207373-8. 
111. Gouzènes L, Desarménien MG, Hussy N, Richard P, Moos FC. Vasopressin regularizes the 
phasic firing pattern of rat hypothalamic magnocellular vasopressin neurons. The Journal of 
Neuroscience. 1998; 18(5): 1879-85. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
112. Poulain DA, Wakerley JB. Electrophysiology of hypothalamic magnocellular neurones 
secreting oxytocin and vasopressin. Neuroscience. 1982; 7(4): 773-808. 
113. Wakerley JB, Poulain DA, Brown D. Comparison of firing patterns in oxytocin- and 
vasopressin-releasing neurones during progressive dehydration. Brain Research. 1978; 148(2): 425-
40. 
114. Elgot A, Hiba OE, Gamrani H. Structural and neurochemical plasticity in both supraoptic and 
paraventricular nuclei of hypothalamus of a desert rodent Meriones Shawi after a severe 
dehydration versus opposite treatment by rehydration: GFAP and vasopressin immunohistochemical 
study. Neuroscience Letters. 2012; 515(1): 55-60. 
115. Hawrylak N, Boone D, Salm AK. The surface density of glial fibrillary acidic protein 
immunopositive astrocytic processes in the rat supraoptic nucleus is reversibly altered by 
dehydration and rehydration. Neuroscience Letters. 1999; 277(1): 57-60. 
116. Hawrylak N, Fleming JC, Salm AK. Dehydration and rehydration selectively and reversibly 
alter glial fibrillary acidic protein immunoreactivity in the rat supraoptic nucleus and subjacent glial 
limitans. Glia. 1998; 22(3): 260-71. 
117. Latzkovits L, Cserr HF, Park JT, Patlak CS, Pettigrew KD, Rimanoczy A. Effects of arginine 
vasopressin and atriopeptin on glial cell volume measured as 3-MG space. American Journal of 
Physiology-Cell physiology. 1993; 33603-8. 
118. Sarfaraz D, Fraser CL. rapid communication Effects of arginine vasopressin on cell volume 
regulation in brain astrocyte in culture. American Journal of Physiology-Endocrinology and 
Metabolism. 1999; 276E596-E601. 
119. Ludwig M, Johnstone LE, Neumann I, Landgraf R, Russell JA. Direct hypertonic stimulation of 
the rat supraoptic nucleus increases c-fos expressionin glial cells rather than magnocellular 
neurones. Cell Tissue Research. 1997; 287(1): 79-90. 
120. Yuan H, Gao B, Duan L, Jiang S, Cao R, Xiong Y-F, Rao Z-R. Acute hyperosmotic stimulus-
induced Fos expression in neurons depends on activation of astrocytes in the supraoptic nucleus of 
rats. Journal of Neuroscience Research. 2009; 88(6): NA-NA. 
121. Jurzak M, Muller AR, Gerstberger R. Characterization of vasopressin receptors in cultured 
cells derived from the region of rat brain circumventricular organs. Neuroscience. 1995; 65(4): 1145-
59. 
122. Syed N, Martens CA, Hsu WH. Arginine vasopressin increases glutamate release and 
intracellular Ca 2+ concentration in hippocampal and cortical astrocytes through two distinct 
receptors. Journal of Neurochemistry. 2007; 103229-37. 
123. Chen Y, Zhao Z, Hertz L. Vasopressin increases [Ca2+]i in differentiated astrocytes by 
activation of V1b/V3 receptors but has no effect in mature cortical neurons. Journal of Neuroscience 
Research. 2000; 60(6): 761-6. 
124. Yamagata K, Takahashi N, Akita N, Nabika T. Arginine vasopressin altered the expression of 
monocarboxylate transporters in cultured astrocytes isolated from stroke-prone spontaneously 
hypertensive rats and congenic SHRpch1_18 rats. Journal of Neuroinflammation. 2017; 14(1): 176-. 
125. Hussy N, Brès V, Rochette M, Duvoid A, Alonso G, Dayanithi G, Moos FC. Osmoregulation of 
vasopressin secretion via activation of neurohypophysial nerve terminals glycine receptors by glial 
taurine. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2001; 
21(18): 7110-6. 
126. Hussy N, Deleuze C, Desarménien MG, Moos FC. Osmotic regulation of neuronal activity: a 
new role for taurine and glial cells in a hypothalamic neuroendocrine structure. Progress in 
Neurobiology. 2000; 62(2): 113-34. 
127. Deleuze C, Duvoid A, Hussy N. Properties and glial origin of osmotic-dependent release of 
taurine from the rat supraoptic nucleus. The Journal of physiology. 1998; 507 ( Pt 2)(Pt 2): 463-71. 
128. Di S, Popescu IR, Tasker JG. Glial control of endocannabinoid heterosynaptic modulation in 
hypothalamic magnocellular neuroendocrine cells. J Neurosci. 2013; 33(46): 18331-42. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
129. Haam J, Halmos KC, Di S, Tasker JG. Nutritional state-dependent ghrelin activation of 
vasopressin neurons via retrograde trans-neuronal-glial stimulation of excitatory GABA circuits. J 
Neurosci. 2014; 34(18): 6201-13. 
130. Windle RJ, Forsling ML, Smith CP, Balment RJ. Patterns of neurohypophysial hormone 
release during dehydration in the rat. Journal of Endocrinology. 1993; 137(2): 311-9. 
131. Bains JS, Potyok A, Ferguson AV. Angiotensin II actions in paraventricular nucleus: functional 
evidence for neurotransmitter role in efferents originating in subfornical organ. Brain Research. 
1992; 599(2): 223-9. 
132. Sakai K, Agassandian K, Morimoto S, Sinnayah P, Cassell MD, Davisson RL, Sigmund CD. Local 
production of angiotensin II in the subfornical organ causes elevated drinking. The Journal of Clinical 
Investigation. 2007; 117(4): 1088-95. 
133. Saxena A, Little JT, Nedungadi TP, Cunningham JT. Angiotensin II type 1a receptors in 
subfornical organ contribute towards chronic intermittent hypoxia-associated sustained increase in 
mean arterial pressure. American journal of physiology Heart and circulatory physiology. 2015; 
308(5): H435-46. 
134. Beresford MJ, Fitzsimons JT. Intracerebroventricular angiotensin II-induced thirst and 
sodium appetite in rat are blocked by the AT1 receptor antagonist, Losartan (DuP 753), but not by 
the AT2 antagonist, CGP 42112B. Experimental Physiology. 1992; 77(5): 761-4. 
135. Gebke E, Müller AR, Jurzak M, Gerstberger R. Angiotensin II-induced calcium signalling in 
neurons and astrocytes of rat circumventricular organs. Neuroscience. 1998; 85(2): 509-20. 
136. Flôr AFL, Alves JLdB, França-Silva MS, Balarini CM, Elias LLK, Ruginsk SG, Antunes-Rodrigues 
J, Braga VA, Cruz JC. Glial Cells Are Involved in ANG-II-Induced Vasopressin Release and Sodium 
Intake in Awake Rats. Frontiers in Physiology. 2018; 91-12. 
137. Stern JE, Son S, Biancardi VC, Zheng H, Sharma N, Patel KP. Astrocytes Contribute to 
Angiotensin II Stimulation of Hypothalamic Neuronal Activity and Sympathetic Outflow. 
Hypertension. 2016; 68(6): 1483-93. 
138. Tardy M, Rolland B, Fages C, Caldani M. Astroglial cells: glucocorticoid target cells in the 
brain. Clin Neuropharmacol. 1984; 7(4): 296-302. 
139. Vielkind U, Walencewicz A, Levine JM, Bohn MC. Type II glucocorticoid receptors are 
expressed in oligodendrocytes and astrocytes. J Neurosci Res. 1990; 27(3): 360-73. 
140. Piechota M, Korostynski M, Golda S, Ficek J, Jantas D, Barbara Z, Przewlocki R. 
Transcriptional signatures of steroid hormones in the striatal neurons and astrocytes. BMC Neurosci. 
2017; 18(1): 37. 
141. Carter BS, Hamilton DE, Thompson RC. Acute and chronic glucocorticoid treatments regulate 
astrocyte-enriched mRNAs in multiple brain regions in vivo. Front Neurosci. 2013; 7139. 
142. Zeng J, Li M, Xiao Z, Chen Y, Chang Q, Tian H, Jin H, Liu X. Rapid elevation of calcium 
concentration in cultured dorsal spinal cord astrocytes by corticosterone. Neurochem Res. 2013; 
38(2): 382-8. 
143. Champeil-Potokar G, Hennebelle M, Latour A, Vancassel S, Denis I. Docosahexaenoic acid 
(DHA) prevents corticosterone-induced changes in astrocyte morphology and function. J Neurochem. 
2016; 136(6): 1155-67. 
144. Chatterjee S, Sikdar SK. Corticosterone treatment results in enhanced release of peptidergic 
vesicles in astrocytes via cytoskeletal rearrangements. Glia. 2013; 61(12): 2050-62. 
145. Unemura K, Kume T, Kondo M, Maeda Y, Izumi Y, Akaike A. Glucocorticoids decrease 
astrocyte numbers by reducing glucocorticoid receptor expression in vitro and in vivo. J Pharmacol 
Sci. 2012; 119(1): 30-9. 
146. Yuan SY, Liu J, Zhou J, Lu W, Zhou HY, Long LH, Hu ZL, Ni L, Wang Y, Chen JG, Wang F. AMPK 
Mediates Glucocorticoids Stress-Induced Downregulation of the Glucocorticoid Receptor in Cultured 
Rat Prefrontal Cortical Astrocytes. PLoS One. 2016; 11(8): e0159513. 
147. Lou YX, Li J, Wang ZZ, Xia CY, Chen NH. Glucocorticoid receptor activation induces decrease 
of hippocampal astrocyte number in rats. Psychopharmacology (Berl). 2018; 235(9): 2529-40. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
148. Zhang H, Zhao Y, Wang Z. Chronic corticosterone exposure reduces hippocampal astrocyte 
structural plasticity and induces hippocampal atrophy in mice. Neurosci Lett. 2015; 59276-81. 
149. Luarte A, Cisternas P, Caviedes A, Batiz LF, Lafourcade C, Wyneken U, Henzi R. Astrocytes at 
the Hub of the Stress Response: Potential Modulation of Neurogenesis by miRNAs in Astrocyte-
Derived Exosomes. Stem Cells Int. 2017; 20171719050. 
150. Oyola MG, Handa RJ. Hypothalamic-pituitary-adrenal and hypothalamic-pituitary-gonadal 
axes: sex differences in regulation of stress responsivity. Stress. 2017; 20(5): 476-94. 
151. Garcia-Caceres C, Lagunas N, Calmarza-Font I, Azcoitia I, Diz-Chaves Y, Garcia-Segura LM, 
Baquedano E, Frago LM, Argente J, Chowen JA. Gender differences in the long-term effects of 
chronic prenatal stress on the HPA axis and hypothalamic structure in rats. 
Psychoneuroendocrinology. 2010; 35(10): 1525-35. 
152. Hertz L, Schousboe I, Hertz L, Schousboe A. Receptor expression in primary cultures of 
neurons or astrocytes. Prog Neuropsychopharmacol Biol Psychiatry. 1984; 8(4-6): 521-7. 
153. Gibbs ME, Hutchinson DS, Summers RJ. Role of beta-adrenoceptors in memory 
consolidation: beta3-adrenoceptors act on glucose uptake and beta2-adrenoceptors on 
glycogenolysis. Neuropsychopharmacology. 2008; 33(10): 2384-97. 
154. Hertz L, Lovatt D, Goldman SA, Nedergaard M. Adrenoceptors in brain: cellular gene 
expression and effects on astrocytic metabolism and [Ca(2+)]i. Neurochem Int. 2010; 57(4): 411-20. 
155. Huang R, Hertz L. Noradrenaline-induced stimulation of glutamine metabolism in primary 
cultures of astrocytes. J Neurosci Res. 1995; 41(5): 677-83. 
156. Gordon GR, Baimoukhametova DV, Hewitt SA, Rajapaksha WR, Fisher TE, Bains JS. 
Norepinephrine triggers release of glial ATP to increase postsynaptic efficacy. Nat Neurosci. 2005; 
8(8): 1078-86. 
157. O'Donnell J, Zeppenfeld D, McConnell E, Pena S, Nedergaard M. Norepinephrine: a 
neuromodulator that boosts the function of multiple cell types to optimize CNS performance. 
Neurochem Res. 2012; 37(11): 2496-512. 
158. Pearson-Leary J, Osborne DM, McNay EC. Role of Glia in Stress-Induced Enhancement and 
Impairment of Memory. Front Integr Neurosci. 2015; 963. 
159. Golombek DA, Rosenstein RE. Physiology of circadian entrainment. Physiol Rev. 2010; 90(3): 
1063-102. 
160. Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M. Entrainment of the circadian clock in 
the liver by feeding. Science. 2001; 291(5503): 490-3. 
161. Buhr ED, Takahashi JS. Molecular components of the Mammalian circadian clock. Handb Exp 
Pharmacol. 2013(217): 3-27. 
162. Takahashi JS, Hong HK, Ko CH, McDearmon EL. The genetics of mammalian circadian order 
and disorder: implications for physiology and disease. Nat Rev Genet. 2008; 9(10): 764-75. 
163. Canal MM, Mohammed NM, Rodríguez JJ. Early programming of astrocyte organization in 
the mouse suprachiasmatic nuclei by light. Chronobiol Int. 2009; 26(8): 1545-58. 
164. Cambras T, López L, Arias JL, Díez-Noguera A. Quantitative changes in neuronal and glial cells 
in the suprachiasmatic nucleus as a function of the lighting conditions during weaning. Brain Res Dev 
Brain Res. 2005; 157(1): 27-33. 
165. Corvetti L, Aztiria E, Domenici L. Reduction of GFAP induced by long dark rearing is not 
restricted to visual cortex. Brain Res. 2006; 1067(1): 146-53. 
166. Lavialle M, Begue A, Papillon C, Vilaplana J. Modifications of retinal afferent activity induce 
changes in astroglial plasticity in the hamster circadian clock. Glia. 2001; 34(2): 88-100. 
167. Marpegan L, Krall TJ, Herzog ED. Vasoactive intestinal polypeptide entrains circadian 
rhythms in astrocytes. J Biol Rhythms. 2009; 24(2): 135-43. 
168. Becquet D, Girardet C, Guillaumond F, François-Bellan AM, Bosler O. Ultrastructural plasticity 
in the rat suprachiasmatic nucleus. Possible involvement in clock entrainment. Glia. 2008; 56(3): 
294-305. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
169. Barca-Mayo O, Pons-Espinal M, Follert P, Armirotti A, Berdondini L, De Pietri Tonelli D. 
Astrocyte deletion of Bmal1 alters daily locomotor activity and cognitive functions via GABA 
signalling. Nat Commun. 2017; 814336. 
170. Tso CF, Simon T, Greenlaw AC, Puri T, Mieda M, Herzog ED. Astrocytes Regulate Daily 
Rhythms in the Suprachiasmatic Nucleus and Behavior. Curr Biol. 2017; 27(7): 1055-61. 
171. Brancaccio M, Patton AP, Chesham JE, Maywood ES, Hastings MH. Astrocytes Control 
Circadian Timekeeping in the Suprachiasmatic Nucleus via Glutamatergic Signaling. Neuron. 2017; 
93(6): 1420-35 e5. 
172. Abrahamson EE, Moore RY. Suprachiasmatic nucleus in the mouse: retinal innervation, 
intrinsic organization and efferent projections. Brain Res. 2001; 916(1-2): 172-91. 
173. Itri J, Colwell CS. Regulation of inhibitory synaptic transmission by vasoactive intestinal 
peptide (VIP) in the mouse suprachiasmatic nucleus. J Neurophysiol. 2003; 90(3): 1589-97. 
174. Leone MJ, Beaule C, Marpegan L, Simon T, Herzog ED, Golombek DA. Glial and light-
dependent glutamate metabolism in the suprachiasmatic nuclei. Chronobiol Int. 2015; 32(4): 573-8. 
175. Beaulé C, Swanstrom A, Leone MJ, Herzog ED. Circadian modulation of gene expression, but 
not glutamate uptake, in mouse and rat cortical astrocytes. PLoS One. 2009; 4(10): e7476. 
176. Brancaccio M, Edwards MD, Patton AP, Smyllie NJ, Chesham JE, Maywood ES, Hastings MH. 
Cell-autonomous clock of astrocytes drives circadian behavior in mammals. Science. 2019; 
363(6423): 187-92. 
  
  
A
cc
ep
te
d 
A
rt
ic
le
 
 
  
 
 
A
cc
ep
te
d 
A
rt
ic
le
 
 
  
 
 
A
cc
ep
te
d 
A
rt
ic
le
 
 
 
 
